Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Vaccines

  Free Subscription


Articles published in J Infect Dis

Retrieve available abstracts of 445 articles:
HTML format



Single Articles


    July 2024
  1. GALAFA B, Chikaonda T, Kudowa E, Sichone S, et al
    Natural carriage of Streptococcus pneumoniae is associated with increased experimental pneumococcal carriage but reduced conjugate vaccine efficacy in a human challenge model.
    J Infect Dis. 2024 Jul 10:jiae341. doi: 10.1093.
    PubMed     Abstract available


  2. CHIME N, Anspach B, Jain V, Laajalahti O, et al
    Phase 3 Study Assessing Lot-to-lot Consistency of RSVPreF3 Vaccine and its Immune Response, Safety, and Reactogenicity When Co-administered with FLU-D-QIV.
    J Infect Dis. 2024 Jul 5:jiae342. doi: 10.1093.
    PubMed     Abstract available



  3. Correction to: Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose.
    J Infect Dis. 2024 Jul 3:jiae336. doi: 10.1093.
    PubMed    


  4. MCCARRON M, Yau TS, Griffin C, Marcenac P, et al
    Do pregnant persons want influenza vaccines? Knowledge, attitudes, perceptions, and practices toward influenza vaccines in 8 low- and middle-income countries.
    J Infect Dis. 2024 Jul 2:jiae340. doi: 10.1093.
    PubMed     Abstract available



  5. Correction to: Progress in Access and Oral Polio Vaccine Coverage Among Children Aged <5 Years in Polio Campaigns After the Political Change in Afghanistan.
    J Infect Dis. 2024 Jul 1:jiae334. doi: 10.1093.
    PubMed    


    June 2024
  6. ANANWORANICH J, Lee IT, Ensz D, Carmona L, et al
    Safety and Immunogenicity of mRNA-1010, an Investigational Seasonal Influenza Vaccine, in Healthy Adults: Final Results From a Phase 1/2 Randomized Trial.
    J Infect Dis. 2024 Jun 27:jiae329. doi: 10.1093.
    PubMed     Abstract available


  7. GOSWAMI J, Baqui AH, Doreski PA, Perez Marc G, et al
    Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.
    J Infect Dis. 2024 Jun 18:jiae316. doi: 10.1093.
    PubMed     Abstract available


  8. LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al
    Hybrid Immunity to SARS-CoV-2 During Pregnancy Provides More Durable Infant Antibody Responses Compared to Natural Infection Alone.
    J Infect Dis. 2024;229:1728-1739.
    PubMed     Abstract available


  9. LEROUX-ROELS I, Maes C, Mancini F, Jacobs B, et al
    Safety and immunogenicity of a 4-component GMMA-based Shigella vaccine in healthy European adults: Stage 1 of a randomized, controlled phase I/II clinical trial.
    J Infect Dis. 2024 Jun 10:jiae273. doi: 10.1093.
    PubMed     Abstract available


  10. AMSTUTZ A, Chammartin F, Audige A, Eichenberger AL, et al
    Antibody and T-cell response to bivalent booster SARS-CoV-2 vaccines in people with compromised immune function (COVERALL-3).
    J Infect Dis. 2024 Jun 7:jiae291. doi: 10.1093.
    PubMed     Abstract available


    May 2024
  11. GODIN A, Connor RI, Degefu HN, Rosato PC, et al
    Nasal and pharyngeal mucosal immunity to poliovirus in children following routine immunization with inactivated polio vaccine (IPV) in the United States of America.
    J Infect Dis. 2024 May 29:jiae264. doi: 10.1093.
    PubMed     Abstract available


  12. TOWNSEND L, Gillespie P, McGrath J, Kenny C, et al
    Health Care Personnel Workdays Lost and Direct Health Care Salary Costs Incurred due to COVID-19 Infection in the Age of Widespread Vaccine Availability.
    J Infect Dis. 2024 May 21:jiae223. doi: 10.1093.
    PubMed     Abstract available


  13. NJIFON HLM, Kenmoe S, Ahmed SM, Roussel Takuissu G, et al
    Epidemiology of Rotavirus in Humans, Animals, and the Environment in Africa: A Systematic Review and Meta-analysis.
    J Infect Dis. 2024;229:1470-1480.
    PubMed     Abstract available


  14. LEE YS, Bang YJ, Yoo S, Park SI, et al
    Analysis of the Immunostimulatory Effects of Cytokine-Expressing Internal Ribosome Entry Site-Based RNA Adjuvants and Their Applications.
    J Infect Dis. 2024;229:1408-1418.
    PubMed     Abstract available


  15. SMITH CL, Didion E, Aung H, Tamilselvan B, et al
    Longitudinal analysis of nursing home residents' T cell responses after SARS-CoV-2 mRNA vaccinations shows influence of biological sex and SARS-CoV-2 infection history.
    J Infect Dis. 2024 May 14:jiae234. doi: 10.1093.
    PubMed     Abstract available


  16. MOTSOENENG BM, Dhar N, Nunes MC, Krammer F, et al
    Hemagglutinin stalk-specific Fc-mediated functions are associated with protection against influenza-illness after seasonal influenza vaccination in pregnant women.
    J Infect Dis. 2024 May 14:jiae241. doi: 10.1093.
    PubMed     Abstract available


  17. PERSSON KEM, Horton JL, Kurtovic L, McCarthy JS, et al
    Declining antibody affinity over time after human vaccination with a Plasmodium falciparum merozoite vaccine candidate.
    J Infect Dis. 2024 May 9:jiae259. doi: 10.1093.
    PubMed     Abstract available


  18. EBINGER JE, Sun N, Joung SY, Sanchez JMS, et al
    Risk of Severe Acute Respiratory Syndrome Coronavirus 2 Infection Following Prior Infection or Vaccination.
    J Infect Dis. 2024 May 8:jiae130. doi: 10.1093.
    PubMed     Abstract available


  19. BALASINGAM S, Dheda K, Fortune S, Gordon SB, et al
    Review of the current TB human infection studies for use in accelerating TB vaccine development: A meeting report.
    J Infect Dis. 2024 May 6:jiae238. doi: 10.1093.
    PubMed     Abstract available


    April 2024
  20. BI Q, Dickerman BA, Nguyen HQ, Martin ET, et al
    Reduced effectiveness of repeat influenza vaccination: distinguishing among within-season waning, recent clinical infection, and subclinical infection.
    J Infect Dis. 2024 Apr 30:jiae220. doi: 10.1093.
    PubMed     Abstract available


  21. JUHL AK, Lokso Dietz L, Schmeltz Sogaard O, Reekie J, et al
    Longitudinal evaluation of SARS-CoV-2 T cell immunity over 2 years following vaccination and infection.
    J Infect Dis. 2024 Apr 30:jiae215. doi: 10.1093.
    PubMed     Abstract available


  22. SIRIVICHAYAKUL C, Biswal S, Saez-Llorens X, Lopez-Medina E, et al
    Efficacy and Safety of a Tetravalent Dengue Vaccine (TAK-003) in Children With Prior Japanese Encephalitis or Yellow Fever Vaccination.
    J Infect Dis. 2024 Apr 29:jiae222. doi: 10.1093.
    PubMed     Abstract available


  23. ORUMAA M, Lahlum EJ, Gulla M, Tota J, et al
    Quadrivalent HPV vaccine effectiveness against cervical intraepithelial lesion grade 2 or worse in Norway: A registry-based study of 0,9 million Norwegian women.
    J Infect Dis. 2024 Apr 25:jiae209. doi: 10.1093.
    PubMed     Abstract available



  24. Correction to: Interim Report of the Reactogenicity and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 XBB-Containing Vaccines.
    J Infect Dis. 2024 Apr 18:jiae186. doi: 10.1093.
    PubMed    


  25. NIKITIN D, Whittles LK, Imai-Eaton JW, White PJ, et al
    Cost-effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection.
    J Infect Dis. 2024 Apr 17:jiae123. doi: 10.1093.
    PubMed     Abstract available


  26. COHEN MS, Marrazzo J
    What if We Had a Vaccine that Prevents Neisseria gonorrhoeae.
    J Infect Dis. 2024 Apr 17:jiae160. doi: 10.1093.
    PubMed    


  27. WALSH EE, Falsey AR, Zareba AM, Jiang Q, et al
    Respiratory Syncytial Virus Prefusion F Vaccination: Antibody Persistence and Revaccination.
    J Infect Dis. 2024 Apr 12:jiae185. doi: 10.1093.
    PubMed     Abstract available


  28. UZZELL CB, Abraham D, Rigby J, Troman CM, et al
    Environmental Surveillance for Salmonella Typhi and its Association With Typhoid Fever Incidence in India and Malawi.
    J Infect Dis. 2024;229:979-987.
    PubMed     Abstract available


  29. SCHMIDT S, Mengistu M, Daffis S, Ahmadi-Erber S, et al
    Alternating Arenavirus Vector Immunization Generates Robust Polyfunctional Genotype Cross-Reactive Hepatitis B Virus-Specific CD8 T-Cell Responses and High Anti-Hepatitis B Surface Antigen Titers.
    J Infect Dis. 2024;229:1077-1087.
    PubMed     Abstract available


  30. THOMPSON KM, Kalkowska DA, Routh JA, Brenner IR, et al
    Modeling Poliovirus Transmission and Responses in New York State.
    J Infect Dis. 2024;229:1097-1106.
    PubMed     Abstract available


  31. SABAWOON W, Seino S, Pason BM, Momin NWS, et al
    Progress in Access and Oral Polio Vaccine Coverage Among Children Aged <5 Years in Polio Campaigns After the Political Change in Afghanistan.
    J Infect Dis. 2024 Apr 10:jiae129. doi: 10.1093.
    PubMed     Abstract available


  32. CHEN MH, Perelygina L, Hao L, Beard RS, et al
    Neutralization of Rubella Vaccine Virus and Immunodeficiency-Related Vaccine-Derived Rubella Viruses by Intravenous Immunoglobulins.
    J Infect Dis. 2024 Apr 9:jiae182. doi: 10.1093.
    PubMed     Abstract available


  33. PONZILACQUA-SILVA B, Dadelahi AS, Abushahba MFN, Moley CR, et al
    Vaccine Elicited Antibodies Restrict Glucose Availability to Control Brucella Infection.
    J Infect Dis. 2024 Apr 8:jiae172. doi: 10.1093.
    PubMed     Abstract available


  34. BARTSCH SM, O'Shea KJ, Weatherwax C, Strych U, et al
    What is the economic benefit of annual COVID-19 vaccination from the adult individual perspective?
    J Infect Dis. 2024 Apr 6:jiae179. doi: 10.1093.
    PubMed     Abstract available


  35. TAIT D, Diacon A, Borges AH, van Brakel E, et al
    Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial.
    J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093.
    PubMed     Abstract available


    March 2024
  36. KAO CM, Rostad CA, Nolan LE, Peters E, et al
    A Phase 1, Double-blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin(R)) Vaccine in Healthy US Adults.
    J Infect Dis. 2024 Mar 27:jiae148. doi: 10.1093.
    PubMed     Abstract available


  37. KALIZANG'OMA A, Swarthout TD, Mwalukomo TS, Kamng'ona A, et al
    Clonal Expansion of a Streptococcus pneumoniae Serotype 3 Capsule Variant Sequence Type 700 With Enhanced Vaccine Escape Potential After 13-Valent Pneumococcal Conjugate Vaccine Introduction.
    J Infect Dis. 2024 Mar 26:jiae040. doi: 10.1093.
    PubMed     Abstract available


  38. FIGUEROA AL, Azzi JR, Eghtesad B, Priddy F, et al
    Safety and Immunogenicity of the mRNA-1273 COVID-19 Vaccine in Solid Organ Transplant Recipients.
    J Infect Dis. 2024 Mar 21:jiae140. doi: 10.1093.
    PubMed     Abstract available


  39. PRUNAS O, Shioda K, Toscano CM, Bastias M, et al
    Estimated population-level impact of pneumococcal conjugate vaccines against all-cause pneumonia mortality among unvaccinated age groups in five Latin American countries.
    J Infect Dis. 2024 Mar 19:jiae144. doi: 10.1093.
    PubMed     Abstract available


  40. KING LM, Andrejko KL, Kabbani S, Tartof SY, et al
    Outpatient visits and antibiotic use due to higher valency pneumococcal vaccine serotypes.
    J Infect Dis. 2024 Mar 18:jiae142. doi: 10.1093.
    PubMed     Abstract available


  41. PRASAD AN, Geisbert TW
    A glass-half-full perspective on negative data in Ebolavirus vaccine studies.
    J Infect Dis. 2024 Mar 15:jiae109. doi: 10.1093.
    PubMed    


  42. VAN TOL S, Fletcher P, Feldmann F, Mukesh RK, et al
    A bivalent Adenovirus-Vectored Vaccine induces a robust humoral response, but does not protect cynomolgus macaques against a lethal challenge with Sudan virus.
    J Infect Dis. 2024 Mar 15:jiae056. doi: 10.1093.
    PubMed     Abstract available


  43. ROSSLER A, Knabl L, Netzl A, Bante D, et al
    Durability of Cross-Neutralizing Antibodies 5.5 Months After Bivalent Coronavirus Disease 2019 Vaccine Booster.
    J Infect Dis. 2024;229:644-647.
    PubMed     Abstract available


  44. GRUNER E, Grossegesse M, Stern D, Ober V, et al
    Mpox-specific immune responses elicited by vaccination or infection in people living with HIV.
    J Infect Dis. 2024 Mar 13:jiae138. doi: 10.1093.
    PubMed     Abstract available


  45. FIERRO C, Brune D, Shaw M, Schwartz H, et al
    Safety and Immunogenicity of a Messenger RNA-Based Cytomegalovirus Vaccine in Healthy Adults: Results From a Phase 1, Randomized, Clinical Trial.
    J Infect Dis. 2024 Mar 13:jiae114. doi: 10.1093.
    PubMed     Abstract available


  46. MUNK C, Reinholdt K, Kjaer AK, Hemmingsen CH, et al
    Prevalence of Human Papillomavirus (HPV) and HPV Type Distribution in Penile Samples in Young Men in Denmark: Results 10 Years After Implementation of a Girls-Only HPV Vaccination Program.
    J Infect Dis. 2024 Mar 12:jiae068. doi: 10.1093.
    PubMed     Abstract available


  47. SEPULVEDA-PACHON IT, Dunne EM, Hanquet G, Baay M, et al
    Effect of pneumococcal conjugate vaccines on viral respiratory infections: a systematic literature review.
    J Infect Dis. 2024 Mar 11:jiae125. doi: 10.1093.
    PubMed     Abstract available


  48. LIM WW, Shuo F, Wong SS, Sullivan SG, et al
    Hemagglutination inhibition antibody titers mediate influenza vaccine efficacy against symptomatic influenza A(H1N1), A(H3N2), and B/Victoria infections.
    J Infect Dis. 2024 Mar 7:jiae122. doi: 10.1093.
    PubMed     Abstract available


  49. COLON W, Oriol Mathieu V, Hural J, Hattingh L, et al
    HIV Diagnostics and Vaccines: It Takes Two to Tango.
    J Infect Dis. 2024 Mar 7:jiae113. doi: 10.1093.
    PubMed     Abstract available


  50. WESTERCAMP N, Osei-Tutu L, Schuerman L, Kariuki SK, et al
    Could less be more? Accounting for fractional-dose regimens and different number of vaccine doses when measuring the impact of the RTS, S/AS01E malaria vaccine.
    J Infect Dis. 2024 Mar 4:jiae075. doi: 10.1093.
    PubMed     Abstract available


  51. CHONG EA, Kumashie KG, Chong ER, Fabrizio J, et al
    Immunologic predictors of vaccine responsiveness in patients with lymphoma and CLL.
    J Infect Dis. 2024 Mar 4:jiae106. doi: 10.1093.
    PubMed     Abstract available


    February 2024
  52. CAO Y, Hayashi CTH, Kumar N
    A novel ex vivo assay to evaluate functional effectiveness of Plasmodium vivax transmission blocking vaccine using Pvs25 transgenic P. berghei.
    J Infect Dis. 2024 Feb 26:jiae102. doi: 10.1093.
    PubMed     Abstract available


  53. WANTUCH PL, Knoot CJ, Robinson LS, Vinogradov E, et al
    A heptavalent O-antigen bioconjugate vaccine exhibits differential functional antibody responses against diverse Klebsiella pneumoniae isolates.
    J Infect Dis. 2024 Feb 24:jiae097. doi: 10.1093.
    PubMed     Abstract available


  54. DZIADULA J, Sabbaj S, Gupta K, Cutter G, et al
    Interferon-Gamma Responses to Chlamydia trachomatis Vaccine Candidate Proteins in Chlamydia-Infected Women with Different Chlamydia Outcomes.
    J Infect Dis. 2024 Feb 23:jiae092. doi: 10.1093.
    PubMed     Abstract available


  55. SHAW CA, Essink B, Harper C, Mithani R, et al
    Safety and Immunogenicity of an mRNA-Based RSV Vaccine Including a 12-Month Booster in a Phase I Clinical Trial in Healthy Older Adults.
    J Infect Dis. 2024 Feb 22:jiae081. doi: 10.1093.
    PubMed     Abstract available


  56. CHALKIAS S, McGhee N, Whatley JL, Essink B, et al
    Interim report of the reactogenicity and immunogenicity of SARS-CoV-2 XBB-containing vaccines.
    J Infect Dis. 2024 Feb 13:jiae067. doi: 10.1093.
    PubMed     Abstract available


  57. FRIEDMAN-KLABANOFF DJ, Berry AA, Travassos MA, Shriver M, et al
    Recombinant full-length Plasmodium falciparum circumsporozoite protein-based vaccine adjuvanted with GLA-LSQ: Results of Phase 1 testing with malaria challenge.
    J Infect Dis. 2024 Feb 8:jiae062. doi: 10.1093.
    PubMed     Abstract available


  58. BURKE RM, Payne DC, McNeal M, Conrey SC, et al
    Correlates of Rotavirus Vaccine Shedding and Seroconversion in a U.S. Cohort of Healthy Infants.
    J Infect Dis. 2024 Feb 8:jiae055. doi: 10.1093.
    PubMed     Abstract available


  59. HU X, Karthigeyan KP, Herbek S, Valencia SM, et al
    Human Cytomegalovirus mRNA-1647 Vaccine Candidate Elicits Potent and Broad Neutralization and Higher Antibody-Dependent Cellular Cytotoxicity Responses Than the gB/MF59 Vaccine.
    J Infect Dis. 2024 Feb 7:jiad593. doi: 10.1093.
    PubMed     Abstract available


    January 2024
  60. SHAW CA, Mithani R, Kapoor A, Dhar R, et al
    Safety, Tolerability and Immunogenicity of a mRNA-based RSV Vaccine in Healthy Young Adults in a Phase 1 Clinical Trial.
    J Infect Dis. 2024 Jan 31:jiae035. doi: 10.1093.
    PubMed     Abstract available


  61. MCCARTHY KN, Hone S, McLoughlin RM, Mills KHG, et al
    IL-17 and IFN-gamma-producing respiratory tissue resident memory CD4 T cells persist for decades in adults immunized as children with whole cell pertussis vaccines.
    J Infect Dis. 2024 Jan 30:jiae034. doi: 10.1093.
    PubMed     Abstract available


  62. LACOURSE SM, Wetzler EA, Aurelio MC, Escudero JN, et al
    Hybrid immunity to SARS-CoV-2 during pregnancy provides more durable infant antibody responses compared to natural infection or vaccination alone.
    J Infect Dis. 2024 Jan 29:jiae046. doi: 10.1093.
    PubMed    


  63. CARROLL TD, Wong T, Morris MK, Di Germanio C, et al
    Vaccine-Boosted CCP Decreases Virus Replication and Hastens Resolution of Infection Despite Transiently Enhancing Disease in SARS-CoV-2-Infected Hamsters.
    J Infect Dis. 2024 Jan 12:jiad568. doi: 10.1093.
    PubMed     Abstract available


  64. HARRER CE, Mayer L, Fathi A, Lassen S, et al
    Identification of a spike-specific CD8+ T cell epitope following vaccination against the Middle East respiratory syndrome coronavirus in humans.
    J Infect Dis. 2024 Jan 9:jiad612. doi: 10.1093.
    PubMed     Abstract available


  65. HOWARD LM, Jensen TL, Goll JB, Gelber CE, et al
    Metabolomic Signatures Differentiate Immune Responses in Avian Influenza Vaccine Recipients.
    J Infect Dis. 2024 Jan 5:jiad611. doi: 10.1093.
    PubMed     Abstract available


    December 2023
  66. SAJKOV D, Woodman R, Honda-Okubo Y, Barbara J, et al
    A Multi-Season Randomised Controlled Trial of Advax-Adjuvanted Seasonal Influenza Vaccine in Participants with Chronic Disease or Older Age.
    J Infect Dis. 2023 Dec 29:jiad589. doi: 10.1093.
    PubMed     Abstract available


  67. ZHANG Y, Zhou Y, Chen J, Wu J, et al
    Vaccination Shapes Within-Host SARS-CoV-2 Diversity of Omicron BA.2.2 Breakthrough Infection.
    J Infect Dis. 2023 Dec 27:jiad572. doi: 10.1093.
    PubMed     Abstract available


  68. WIDAGDO W, Bastian AR, Jastorff AM, Scheys I, et al
    Concomitant Administration of Ad26.RSV.preF/RSV preF Protein Vaccine and High-dose Influenza Vaccine in Adults 65 Years and Older: a Noninferiority Trial.
    J Infect Dis. 2023 Dec 22:jiad594. doi: 10.1093.
    PubMed     Abstract available


  69. HERMIDA N, Ferguson M, Leroux-Roels I, Pagnussat S, et al
    Safety and Immunogenicity of Respiratory Syncytial Virus Pre-fusion Maternal Vaccine Co-administered with Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study.
    J Infect Dis. 2023 Dec 22:jiad560. doi: 10.1093.
    PubMed     Abstract available


  70. YAMAMOTO S, Matsuda K, Maeda K, Horii K, et al
    Preinfection Neutralizing Antibodies, Omicron BA.5 Breakthrough Infection, and Long COVID: A Propensity Score-Matched Analysis.
    J Infect Dis. 2023;228:1652-1661.
    PubMed     Abstract available


  71. PENETRA SLS, Santos HFP, Resende PC, Bastos LS, et al
    SARS-CoV-2 Reinfection Cases in a Household-Based Prospective Cohort in Rio de Janeiro.
    J Infect Dis. 2023;228:1680-1689.
    PubMed     Abstract available


  72. F SCHWARZ T, Hwang SJ, Ylisastigui P, Liu CS, et al
    Immunogenicity and safety following one dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: a phase 3 trial.
    J Infect Dis. 2023 Dec 14:jiad546. doi: 10.1093.
    PubMed     Abstract available


  73. HUH K, Kang M, Kim YE, Choi Y, et al
    Risk of Severe COVID-19 and Protective Effectiveness of Vaccination Among Solid Organ Transplant Recipients.
    J Infect Dis. 2023 Dec 14:jiad501. doi: 10.1093.
    PubMed     Abstract available


  74. ELLINGSON MK, Weinberger DM, van der Linden M, Perniciaro S, et al
    Potential Impact of Higher-Valency Pneumococcal Conjugate Vaccines Among Adults in Different Localities in Germany.
    J Infect Dis. 2023 Dec 6:jiad538. doi: 10.1093.
    PubMed     Abstract available


  75. TENFORDE MW, Weber ZA, Yang DH, DeSilva MB, et al
    Influenza vaccine effectiveness against influenza-A-associated emergency department, urgent care, and hospitalization encounters among U.S. adults, 2022-2023.
    J Infect Dis. 2023 Dec 2:jiad542. doi: 10.1093.
    PubMed     Abstract available


    November 2023
  76. TUTTLE DJ, Castanha PMS, Nasser A, Wilkins MS, et al
    SARS-CoV-2 mRNA vaccines induce greater complement activation and decreased viremia and Nef antibodies in men with HIV-1.
    J Infect Dis. 2023 Nov 30:jiad544. doi: 10.1093.
    PubMed     Abstract available


  77. FELL DB, Russell M, Fung SG, Swayze S, et al
    Effectiveness of maternal influenza vaccination during pregnancy against laboratory-confirmed seasonal influenza among infants under 6 months of age in Ontario, Canada.
    J Infect Dis. 2023 Nov 29:jiad539. doi: 10.1093.
    PubMed     Abstract available


  78. LEE K, Williams KV, Englund JA, Sullivan SG, et al
    The potential benefits of delaying seasonal influenza vaccine selections for the Northern Hemisphere: a retrospective modeling study in the United States.
    J Infect Dis. 2023 Nov 29:jiad541. doi: 10.1093.
    PubMed     Abstract available


  79. KARABA AH, Morgenlander WR, Johnston TS, Hage C, et al
    Epitope Mapping of SARS-CoV-2 Spike Antibodies in Vaccinated Kidney Transplant Recipients Reveals Poor Spike Coverage Compared to Healthy Controls.
    J Infect Dis. 2023 Nov 29:jiad534. doi: 10.1093.
    PubMed     Abstract available


  80. CISZEWSKI J, Taniuchi M, Lee B, Colgate ER, et al
    Differences in Rotavirus Shedding and Duration by Infant Oral Rotavirus Vaccination Status in Dhaka, Bangladesh 2011 - 2014.
    J Infect Dis. 2023 Nov 29:jiad502. doi: 10.1093.
    PubMed     Abstract available


  81. BLAZEVIC A, Edwards RL, Xia M, Eickhoff CS, et al
    Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guerin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
    J Infect Dis. 2023 Nov 29:jiad441. doi: 10.1093.
    PubMed     Abstract available


  82. GIULIANO AR, Palefsky JM, Goldstone SE, Dubin B, et al
    High Risk of New HPV Infection Acquisition Among Unvaccinated Young Men.
    J Infect Dis. 2023 Nov 28:jiad485. doi: 10.1093.
    PubMed     Abstract available


  83. PICHICHERO ME, Xu L, Gonzalez E, Pham M, et al
    Variability of Vaccine Responsiveness in Young Children.
    J Infect Dis. 2023 Nov 22:jiad524. doi: 10.1093.
    PubMed     Abstract available


  84. LU X, Liu F, Tzeng WP, York IA, et al
    Antibody-mediated Suppression Regulates the Humoral Immune Response to Influenza Vaccination in Humans.
    J Infect Dis. 2023 Nov 20:jiad493. doi: 10.1093.
    PubMed     Abstract available


  85. BENNETT C, Rivers EJ, Woo W, Bloch M, et al
    Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-CoV-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial.
    J Infect Dis. 2023 Nov 16:jiad508. doi: 10.1093.
    PubMed     Abstract available


  86. HAIDAR G, Hodges JC, Bilderback A, Lukanski A, et al
    Prospective assessment of humoral and cellular immune responses to a 3rd COVID-19 mRNA vaccine dose among immunocompromised individuals.
    J Infect Dis. 2023 Nov 16:jiad511. doi: 10.1093.
    PubMed     Abstract available


  87. DAVIES KA, Welch SR, Jain S, Sorvillo TE, et al
    Fluorescent and Bioluminescent Reporter Mouse-Adapted Ebola Viruses Maintain Pathogenicity and Can Be Visualized in Vivo.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  88. MORI M, Doi T, Murata M, Moriyama Y, et al
    Impact of nutritional status on antibody titer after booster mRNA COVID-19 vaccine among elderly adults in Japan.
    J Infect Dis. 2023 Nov 14:jiad495. doi: 10.1093.
    PubMed     Abstract available


  89. BUSHMAKER T, Feldmann F, Lovaglio J, Saturday G, et al
    Limited Benefit of Postexposure Prophylaxis With VSV-EBOV in Ebola Virus-Infected Rhesus Macaques.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  90. O'DONNELL KL, Callison J, Feldmann H, Hoenen T, et al
    Single-Dose Treatment With Vesicular Stomatitis Virus-Based Ebola Virus Vaccine Expressing Ebola Virus-Specific Artificial Micro-RNA Does Not Protect Mice From Lethal Disease.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  91. LASRADO N, Barouch DH
    SARS-CoV-2 Hybrid Immunity: The Best of Both Worlds.
    J Infect Dis. 2023;228:1311-1313.
    PubMed     Abstract available


  92. ZHONG S, Ng TWY, Skowronski DM, Iuliano AD, et al
    Standard-dose versus MF59-adjuvanted, high-dose or recombinant-hemagglutinin influenza vaccine immunogenicity in older adults: comparison of A(H3N2) antibody response by prior season's vaccine status.
    J Infect Dis. 2023 Nov 10:jiad497. doi: 10.1093.
    PubMed     Abstract available


  93. POUKKA E, van Roekel C, Turunen T, Baum U, et al
    Effectiveness of vaccines and monoclonal antibodies against respiratory syncytial virus: Generic protocol for register-based cohort study.
    J Infect Dis. 2023 Nov 1:jiad484. doi: 10.1093.
    PubMed     Abstract available


    October 2023
  94. ASAMOAH-BOAHENG M, Grunau B, Karim ME, Kirkham TL, et al
    The association of post-COVID-related symptoms and preceding SARS-CoV-2 infection among fully vaccinated paramedics in Canada.
    J Infect Dis. 2023 Oct 31:jiad475. doi: 10.1093.
    PubMed     Abstract available


  95. RUDOLPH AE, Khan FL, Shah A, Singh TG, et al
    Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against symptomatic COVID-19 among immunocompetent individuals testing at a large US retail pharmacy.
    J Infect Dis. 2023 Oct 31:jiad474. doi: 10.1093.
    PubMed     Abstract available


  96. HILL PC, Cobelens F, Martinez L, Garcia-Basteiro A, et al
    Correspondence Regarding: McShane H. Improving TB vaccine trial efficiency: A tough nut to crack. J Infect Dis. 2023.
    J Infect Dis. 2023 Oct 28:jiad466. doi: 10.1093.
    PubMed    


  97. JAIROCE C, Macia D, Torres-Yaguana JP, Mayer L, et al
    RTS, S/AS02A malaria vaccine-induced IgG responses equally recognize native-like fucosylated and non-fucosylated Plasmodium falciparum circumsporozoite proteins.
    J Infect Dis. 2023 Oct 27:jiad471. doi: 10.1093.
    PubMed     Abstract available


  98. TURCINOVIC J, Kuhfeldt K, Sullivan M, Landaverde L, et al
    Transmission Dynamics and Rare Clustered Transmission Within an Urban University Population Before Widespread Vaccination.
    J Infect Dis. 2023 Oct 19:jiad397. doi: 10.1093.
    PubMed     Abstract available


  99. DUPREX WP, Dutch RE
    Paramyxoviruses: Pathogenesis, Vaccines, Antivirals, and Prototypes for Pandemic Preparedness.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  100. DESCHAMPS AM, DeRocco AJ, Bok K, Patterson LJ, et al
    Prototype Pathogens for Vaccine and Monoclonal Antibody Countermeasure Development: NIAID Workshop Process and Outcomes for Viral Families of Pandemic Potential.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  101. MORABITO KM, Cassetti MC, DeRocco AJ, Deschamps AM, et al
    Viral Prototypes for Pandemic Preparedness: The Road Ahead.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  102. ADHIKARI EH, Lu P, Kang YJ, McDonald AR, et al
    Diverging maternal and cord antibody functions from SARS-CoV-2 infection and vaccination in pregnancy.
    J Infect Dis. 2023 Oct 10:jiad421. doi: 10.1093.
    PubMed     Abstract available


  103. DE ARAUJO LP, Santos NCM, Corsetti PP, de Almeida LA, et al
    Immunoinformatic approach for rational identification of immunogenic peptides against host entry and/or exit monkeypox proteins and potential multi-epitope vaccine construction.
    J Infect Dis. 2023 Oct 7:jiad443. doi: 10.1093.
    PubMed     Abstract available


  104. HSU FC, Pan LC, Huang YF, Yang CH, et al
    A Dynamic Model for Estimating the Retention Duration of Neutralizing Antibody Titers after Vaccination in a COVID-19 Convalescent Population.
    J Infect Dis. 2023 Oct 5:jiad431. doi: 10.1093.
    PubMed     Abstract available


  105. GREWAL R, Buchan SA, Nguyen L, Nasreen S, et al
    Effectiveness of mRNA COVID-19 monovalent and bivalent vaccine booster doses against Omicron severe outcomes among adults aged >/=50 years in Ontario, Canada: a Canadian Immunization Research Network (CIRN) Study.
    J Infect Dis. 2023 Oct 5:jiad419. doi: 10.1093.
    PubMed     Abstract available


  106. CHIRENJE ZM, Laher F, Dintwe O, Muyoyeta M, et al
    Protein dose-sparing effect of AS01B adjuvant in a randomized preventive HIV vaccine trial of ALVAC-HIV (vCP2438) and adjuvanted bivalent subtype C gp120.
    J Infect Dis. 2023 Oct 5:jiad434. doi: 10.1093.
    PubMed     Abstract available


  107. SKARBINSKI J, Nugent JR, Wood MS, Liu L, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Genomic Variation Associated With Breakthrough Infection in Northern California: A Retrospective Cohort Study.
    J Infect Dis. 2023;228:878-888.
    PubMed     Abstract available


  108. ATMAR RL, Ettayebi K, Ramani S, Neill FH, et al
    A Bivalent Human Norovirus Vaccine Induces Homotypic and Heterotypic Neutralizing Antibodies.
    J Infect Dis. 2023 Oct 2:jiad401. doi: 10.1093.
    PubMed     Abstract available


    September 2023
  109. MADSEN AMR, Schaltz-Buchholzer F, Nielsen S, Benfield T, et al
    Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: a randomized controlled trial.
    J Infect Dis. 2023 Sep 29:jiad422. doi: 10.1093.
    PubMed     Abstract available


  110. AMIN AB, Cates JE, Liu Z, Wu J, et al
    Rotavirus genotypes in the post-vaccine era: A systematic review and meta-analysis of global, regional, and temporal trends in settings with and without rotavirus vaccine introduction.
    J Infect Dis. 2023 Sep 21:jiad403. doi: 10.1093.
    PubMed     Abstract available


  111. QURESHI H, Mahmood H, Sabry A, Hermez J, et al
    Barriers and Strategies for Hepatitis B and C Elimination in Pakistan.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  112. LEROUX-ROELS I, Van Ranst M, Vandermeulen C, Abeele CV, et al
    Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
    J Infect Dis. 2023 Sep 12:jiad321. doi: 10.1093.
    PubMed     Abstract available


  113. FROBERG J, Koomen VJCH, van der Gaast-de Jongh CE, Philipsen R, et al
    Primary exposure to SARS-CoV-2 via infection or vaccination determines mucosal antibody-dependent ACE2 binding inhibition.
    J Infect Dis. 2023 Sep 7:jiad385. doi: 10.1093.
    PubMed     Abstract available


  114. MARTIN JM, Moehling Geffel K, Ortiz MA, Rajasundaram D, et al
    Differential Induction of Interferon Stimulated Genes by Cell-based Versus Egg-based Quadrivalent Influenza Vaccines in Children During the 2018-19 Season.
    J Infect Dis. 2023 Sep 4:jiad380. doi: 10.1093.
    PubMed     Abstract available


  115. GRANT LR, Begier E, Theilacker C, Barry R, et al
    Multicountry review of Streptococcus pneumoniae serotype distribution among adults with community-acquired pneumonia.
    J Infect Dis. 2023 Sep 4:jiad379. doi: 10.1093.
    PubMed     Abstract available



  116. Correction to: Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-up Compared With Natural Infection.
    J Infect Dis. 2023 Sep 1:jiad375. doi: 10.1093.
    PubMed    


    August 2023
  117. SARIOL A, Vickers MA, Christensen SM, Weiskopf D, et al
    Monovalent SARS-CoV-2 mRNA vaccine does not boost Omicron-specific immune response in diabetic and control pediatric patients.
    J Infect Dis. 2023 Aug 25:jiad366. doi: 10.1093.
    PubMed     Abstract available


  118. SUNG MH, Billings W, Carlock MA, Hanley HB, et al
    Assessment of humoral immune responses to repeated influenza vaccination in a multiyear cohort: a five-year follow-up.
    J Infect Dis. 2023 Aug 25:jiad319. doi: 10.1093.
    PubMed     Abstract available


  119. LARIVIERE Y, Garcia-Fogeda I, Zola Matuvanga T, Isekah Osang'ir B, et al
    Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
    J Infect Dis. 2023 Aug 24:jiad350. doi: 10.1093.
    PubMed     Abstract available


  120. HILL PC, Cobelens F, Martinez L, Behr MA, et al
    An aspiration to radically shorten phase 3 TB vaccine trials.
    J Infect Dis. 2023 Aug 22:jiad356. doi: 10.1093.
    PubMed     Abstract available


  121. MCSHANE H
    Improving TB vaccine trial efficiency: A tough nut to crack.
    J Infect Dis. 2023 Aug 21:jiad360. doi: 10.1093.
    PubMed    


  122. DONATO CM, Handley A, Byars SG, Bogdanovic-Sakran N, et al
    "Vaccine take of RV3-BB rotavirus vaccine observed in Indonesian infants regardless of HBGA status".
    J Infect Dis. 2023 Aug 18:jiad351. doi: 10.1093.
    PubMed     Abstract available


  123. DUARTE LF, Vazquez Y, Diethelm-Varela B, Pavez V, et al
    Differential Sars-Cov-2-Specific Humoral Response in Inactivated Virus-Vaccinated, Convalescent, and Breakthrough Subjects.
    J Infect Dis. 2023 Aug 12:jiad320. doi: 10.1093.
    PubMed     Abstract available


  124. KAPIL P, Wang Y, Zimmerman L, Gaykema M, et al
    "Repeated B. pertussis Infections are Required to Reprogram Acellular Pertussis Vaccine-primed Host Responses in the Baboon Model".
    J Infect Dis. 2023 Aug 11:jiad332. doi: 10.1093.
    PubMed     Abstract available


  125. WANG FZ, Zhang CH, Tang L, Rodewald LE, et al
    An observational prospective cohort study of vaccine effectiveness against SARS-CoV-2 infection of an aerosolized, inhaled adenovirus-type-5-vectored COVID-19 vaccine given as a second booster dose in Guangzhou city, China.
    J Infect Dis. 2023 Aug 11:jiad338. doi: 10.1093.
    PubMed     Abstract available


  126. NOBLE CC, Messina NL, Pittet LF, Curtis N, et al
    Interpreting the results of trials of BCG vaccination for protection against COVID-19.
    J Infect Dis. 2023 Aug 10:jiad316. doi: 10.1093.
    PubMed     Abstract available


  127. ROUPHAEL NG, Branche AR, Diemert DJ, Falsey AR, et al
    Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.
    J Infect Dis. 2023 Aug 10:jiad323. doi: 10.1093.
    PubMed     Abstract available


  128. YOON JG, Kim YE, Choi MJ, Choi WS, et al
    Herpes zoster reactivation after mRNA and adenovirus-vectored coronavirus disease 2019 vaccination: Analysis of National Health Insurance Database.
    J Infect Dis. 2023 Aug 7:jiad297. doi: 10.1093.
    PubMed     Abstract available


  129. HALL VG, Teh BW
    COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  130. ANTINORI A, Bausch-Jurken M
    The Burden of COVID-19 in the Immunocompromised Patient: Implications for Vaccination and Needs for the Future.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  131. BONANNI P, Ceddia F, Dawson R
    A Call to Action: Current Challenges and Considerations for COVID-19 Vaccination in Immunocompromised Populations.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  132. SUBRAMANIAN V
    Susceptibility to SARS-CoV-2 Infection and Immune Responses to COVID-19 Vaccination Among Recipients of Solid Organ Transplants.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  133. ROUPHAEL N, Bausch-Jurken M
    COVID-19 Vaccination Among Patients Receiving Maintenance Renal Replacement Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  134. WILLICOMBE M
    Foreword: Preventing COVID-19 Among the Immunocompromised Population.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  135. PARIS R
    SARS-CoV-2 Infection and Response to COVID-19 Vaccination in Patients With Primary Immunodeficiencies.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  136. FINCKH A, Ciurea A, Raptis CE, Rubbert-Roth A, et al
    Susceptibility to COVID-19 and Immunologic Response to Vaccination in Patients With Immune-Mediated Inflammatory Diseases.
    J Infect Dis. 2023;228.
    PubMed     Abstract available


  137. LIU J, Cao F, Luo C, Guo Y, et al
    Stroke Following COVID-19 Vaccination: Evidence Based on Different Designs of Real-World Studies.
    J Infect Dis. 2023 Aug 3:jiad306. doi: 10.1093.
    PubMed     Abstract available


  138. BRAUNSTEIN SL, Wahnich A, Lazar R
    COVID-19 outcomes among people with HIV and COVID-19 in New York City.
    J Infect Dis. 2023 Aug 3:jiad311. doi: 10.1093.
    PubMed     Abstract available


  139. REMICH S, Kitchin N, Peterson J, Li P, et al
    A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses of a Clostridioides difficile Vaccine in Healthy US Adults 65 to 85 Years of Age.
    J Infect Dis. 2023 Aug 2:jiad307. doi: 10.1093.
    PubMed     Abstract available


    July 2023
  140. POWELL JG, Goble SR, Debes JD
    Re-vaccination For Hepatitis B in Previous Non-Responders Following Hepatitis C Eradication.
    J Infect Dis. 2023 Jul 31:jiad301. doi: 10.1093.
    PubMed     Abstract available


  141. KARRON RA, Luongo C, Woods S, Oliva J, et al
    Evaluation of the live-attenuated intranasal respiratory syncytial virus (RSV) vaccine RSV/6120/DeltaNS2/1030s in RSV-seronegative young children.
    J Infect Dis. 2023 Jul 26:jiad281. doi: 10.1093.
    PubMed     Abstract available


  142. SAEZ-LLORENS X, Norero X, Mussi-Pinhata MM, Luciani K, et al
    Safety and immunogenicity of a ChAd155-vectored respiratory syncytial virus vaccine in infants 6-7 months of age: a phase 1/2 randomized trial.
    J Infect Dis. 2023 Jul 21:jiad271. doi: 10.1093.
    PubMed     Abstract available


  143. MALHERBE DC, Kimble JB, Atyeo C, Fischinger S, et al
    A single dose intranasal combination panebolavirus vaccine.
    J Infect Dis. 2023 Jul 20:jiad266. doi: 10.1093.
    PubMed     Abstract available


  144. EL SAHLY HM, Yildirim I, Frey SE, Winokur P, et al
    Safety and Immunogenicity of a Delayed Heterologous Avian Influenza A(H7N9) Vaccine Boost Following Different Priming Regimens: A Randomized Clinical Trial.
    J Infect Dis. 2023 Jul 19:jiad276. doi: 10.1093.
    PubMed     Abstract available


  145. MARZI A, Feldmann H
    Marburg Virus Disease: Global Threat or Isolated Events?
    J Infect Dis. 2023;228:103-105.
    PubMed    


  146. JAGER M, Diem G, Sahanic S, Fux V, et al
    Immunity of Heterologously and Homologously Boosted or Convalescent Individuals Against Omicron BA.1, BA.2, and BA.4/5 Variants.
    J Infect Dis. 2023;228:160-168.
    PubMed     Abstract available


  147. ROA CC, de Los Reyes MRA, Plennevaux E, Smolenov I, et al
    Superior boosting of neutralizing titers against Omicron SARS-CoV-2 variants by heterologous SCB-2019 vaccine vs a homologous booster in CoronaVac-primed adults.
    J Infect Dis. 2023 Jul 13:jiad262. doi: 10.1093.
    PubMed     Abstract available


  148. COMEAUX CA, Bart S, Bastian AR, Klyashtornyy V, et al
    Safety, Immunogenicity, and Regimen Selection of Ad26.RSV.preF-based Vaccine Combinations: A Randomized, Double-blind, Placebo-Controlled, Phase 1/2a Study.
    J Infect Dis. 2023 Jul 11:jiad220. doi: 10.1093.
    PubMed     Abstract available


  149. FERNANDEZ-GONZALEZ M, Agullo V, Garcia JA, Padilla S, et al
    T-cell immunity against SARS-CoV-2 measured by an interferon-gamma release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with Delta or Omicron variants.
    J Infect Dis. 2023 Jul 7:jiad260. doi: 10.1093.
    PubMed     Abstract available


    June 2023
  150. PAULSEN GC, Frenck R, Tomashek KM, Alarcon RM, et al
    Safety and Immunogenicity of an Andes Virus DNA Vaccine by Needle-Free Injection: a Randomized, Controlled Phase 1 Study.
    J Infect Dis. 2023 Jun 28:jiad235. doi: 10.1093.
    PubMed     Abstract available


  151. FUJITA S, Uriu K, Pan L, Nao N, et al
    Impact of imprinted immunity induced by mRNA vaccination in an experimental animal model.
    J Infect Dis. 2023 Jun 27:jiad230. doi: 10.1093.
    PubMed     Abstract available


  152. SALEEM AF, Parkar S, Zehra SM, Kazi Z, et al
    Two-year duration of immunity of inactivated poliovirus vaccine: A follow-up study in Pakistan in 2020.
    J Infect Dis. 2023 Jun 27:jiad237. doi: 10.1093.
    PubMed     Abstract available


  153. MANDOLO J, Parker EPK, Bronowski C, Sindhu KNC, et al
    Association between maternal breastmilk microbiota composition and rotavirus vaccine response in African, Asian, and European infants: a prospective cohort study.
    J Infect Dis. 2023 Jun 26:jiad234. doi: 10.1093.
    PubMed     Abstract available


  154. VOORMAN A, Lyons H, Shuab F, Adamu US, et al
    Evaluation of novel oral polio vaccine type 2 SIA impact in a large outbreak of circulating vaccine-derived poliovirus in Nigeria.
    J Infect Dis. 2023 Jun 26:jiad222. doi: 10.1093.
    PubMed     Abstract available


  155. WOOLSEY C, Strampe J, Fenton KA, Agans KN, et al
    A recombinant vesicular stomatitis virus-based vaccine provides postexposure protection against Bundibugyo ebolavirus infection.
    J Infect Dis. 2023 Jun 8:jiad207. doi: 10.1093.
    PubMed     Abstract available


  156. MARZI A, Feldmann F, O'Donnell KL, Hanley PW, et al
    Preexisting immunity does not prevent efficacy of VSV-based filovirus vaccines in nonhuman primates.
    J Infect Dis. 2023 Jun 8:jiad208. doi: 10.1093.
    PubMed     Abstract available


  157. EMBACHER S, Maertens K, Herzog SA
    Half-life estimation of pertussis-specific maternal antibodies in (pre)term infants after in-pregnancy tetanus, diphtheria, acellular pertussis vaccination.
    J Infect Dis. 2023 Jun 7:jiad212. doi: 10.1093.
    PubMed     Abstract available


  158. WANG W, Goguet E, Paz Padilla S, Vassell R, et al
    Bivalent COVID-19 vaccine antibody responses to Omicron variants suggest that responses to divergent variants would be improved with matched vaccine antigens.
    J Infect Dis. 2023 Jun 6:jiad111. doi: 10.1093.
    PubMed     Abstract available


  159. REYES Y, St Jean DT, Bowman NM, Gonzalez F, et al
    Non-secretor phenotype is associated with less risk of rotavirus-associated acute gastroenteritis in a vaccinated Nicaraguan birth cohort.
    J Infect Dis. 2023 Jun 5:jiad202. doi: 10.1093.
    PubMed     Abstract available


    May 2023
  160. WEI F, Alberts CJ, Albuquerque A, Clifford GM, et al
    Impact of human papillomavirus vaccine against anal human papillomavirus infection, anal intraepithelial neoplasia, and recurrence of anal intraepithelial neoplasia: a systematic review and meta-analysis.
    J Infect Dis. 2023 May 31:jiad183. doi: 10.1093.
    PubMed     Abstract available


  161. KEELEY AJ, Groves D, Armitage EP, Senghore E, et al
    Streptococcus pyogenes colonization in children aged 24-59 months in The Gambia: Impact of Live Attenuated Influenza Vaccine and associated serological responses.
    J Infect Dis. 2023 May 29:jiad153. doi: 10.1093.
    PubMed     Abstract available


  162. SCHALTZ-BUCHHOLZER F, Aaby P, Silva I, Monteiro I, et al
    Mortality Risk Among Frail Neonates and Maternal BCG Vaccine Scar Status: Observational Study From Guinea-Bissau.
    J Infect Dis. 2023;227:1237-1244.
    PubMed     Abstract available


  163. FRIES L, Formica N, Mallory RM, Zhou H, et al
    Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination.
    J Infect Dis. 2023 May 21:jiad163. doi: 10.1093.
    PubMed     Abstract available


  164. XIA X, Tan ZM, Wan P, Zheng H, et al
    Environmental impact assessment for the use of an orally aerosolised adenovirus type-5 vector-based COVID-19 vaccine in randomised clinical trials.
    J Infect Dis. 2023 May 18:jiad134. doi: 10.1093.
    PubMed     Abstract available


  165. WOOLSEY C, Borisevich V, Agans KN, O'Toole R, et al
    A highly attenuated pan-filovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and three species of Ebolavirus.
    J Infect Dis. 2023 May 12:jiad157. doi: 10.1093.
    PubMed     Abstract available


  166. MORAIS S, Wissing MD, Khosrow-Khavar F, Burchell AN, et al
    Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study.
    J Infect Dis. 2023;227:1173-1184.
    PubMed     Abstract available


  167. WEINBERG A, Schmid DS, Leung J, Johnson MJ, et al
    Predictors of Five-Year Persistence of Antibody Responses to Zoster Vaccines.
    J Infect Dis. 2023 May 4:jiad132. doi: 10.1093.
    PubMed     Abstract available


  168. ASSANTACHAI P, Niyomnaitham S, Chatthanawaree W, Intalapaporn S, et al
    Immunogenicity and reactogenicity of mRNA COVID-19 vaccine booster administered by intradermal or intramuscular route in Thai Older adults.
    J Infect Dis. 2023 May 4:jiad133. doi: 10.1093.
    PubMed     Abstract available


    April 2023
  169. SINGH G, Abbad A, Tcheou J, Mendu DR, et al
    Binding and avidity signatures of polyclonal sera from individuals with different exposure histories to SARS-CoV-2 infection, vaccination, and Omicron breakthrough infections.
    J Infect Dis. 2023 Apr 27:jiad116. doi: 10.1093.
    PubMed     Abstract available


  170. IONESCU IG, Skowronski DM, Sauvageau C, Chuang E, et al
    BNT162b2 Effectiveness Against Delta and Omicron Variants of Severe Acute Respiratory Syndrome Coronavirus 2 in Adolescents Aged 12-17 Years, by Dosing Interval and Duration.
    J Infect Dis. 2023;227:1073-10783.
    PubMed     Abstract available


  171. ALVAREZ-HEREDIA P, Reina-Alfonso I, Dominguez-Del Castillo JJ, Gutierrez-Gonzalez C, et al
    Accelerated T cell immunosenescence in CMV-seropositive individuals after SARS-CoV-2 infection.
    J Infect Dis. 2023 Apr 26:jiad119. doi: 10.1093.
    PubMed     Abstract available


  172. HOEVE CE, de Gier B, Huiberts AJ, de Melker HE, et al
    Vaccine effectiveness against SARS-CoV-2 Delta and Omicron infection and infectiousness within households in the Netherlands between July 2021 and August 2022.
    J Infect Dis. 2023 Apr 24:jiad110. doi: 10.1093.
    PubMed     Abstract available


  173. JORDAN E, Kabir G, Schultz S, Silbernagl G, et al
    Reduced Respiratory Syncytial Virus Load, Symptoms, and Infections: a Human Challenge Trial of MVA-BN-RSV Vaccine.
    J Infect Dis. 2023 Apr 20:jiad108. doi: 10.1093.
    PubMed     Abstract available



  174. Correction to: Vaccine Effectiveness Against 12-Month Incident and Persistent Anal Human Papillomavirus Infection Among Gay, Bisexual, and Other Men Who Have Sex With Men.
    J Infect Dis. 2023 Apr 19:jiad097. doi: 10.1093.
    PubMed    


  175. BUBAK AN, Coughlan C, Posey J, Saviola AJ, et al
    Zoster-Associated Prothrombotic Plasma Exosomes and Increased Stroke Risk.
    J Infect Dis. 2023;227:993-1001.
    PubMed     Abstract available


  176. BLANKSON JN
    Bivalent COVID Vaccines; Can the Original Antigenic Sin be Forgiven?
    J Infect Dis. 2023 Apr 5:jiad073. doi: 10.1093.
    PubMed    


  177. EL-HENEIDY A, Grimwood K, Lambert SB, Ware RS, et al
    Interference between enteric viruses and live-attenuated rotavirus vaccine virus in a healthy Australian birth cohort.
    J Infect Dis. 2023 Apr 4:jiad094. doi: 10.1093.
    PubMed     Abstract available


  178. TANG L, Wang FZ, Rodewald LE, Wang XY, et al
    Real-world effectiveness of primary series and booster doses of inactivated COVID-19 vaccine against Omicron BA.2 variant infection in China: a retrospective cohort study.
    J Infect Dis. 2023 Apr 3:jiad090. doi: 10.1093.
    PubMed     Abstract available


    March 2023
  179. XIANG J, Chang Q, McLinden JH, Bhattarai N, et al
    Characterization of "off-target" immune modulation induced by live attenuated yellow fever vaccine.
    J Infect Dis. 2023 Mar 30:jiad086. doi: 10.1093.
    PubMed     Abstract available


  180. VAN EER K, Middeldorp M, Dzebisasjvili T, Lamkaraf N, et al
    Effects of two and three vaccinations with the bivalent HPV vaccine on the prevalence and load of HPV in clearing and persistent infections in young women.
    J Infect Dis. 2023 Mar 29:jiad080. doi: 10.1093.
    PubMed     Abstract available


  181. NURMI V, Knight C, Estcourt L, Hepojoki J, et al
    The relationship between SARS-CoV-2 neutralising antibody titres and avidity in plasma collected from convalescent non-vaccinated and vaccinated blood donors.
    J Infect Dis. 2023 Mar 27:jiad070. doi: 10.1093.
    PubMed     Abstract available


  182. SMITH CL, Bednarchik B, Aung H, Wilk DJ, et al
    Humoral and Cellular Immunity Induced by Adjuvanted and Standard Trivalent Influenza Vaccine in Older Nursing Home Residents.
    J Infect Dis. 2023 Mar 23:jiad071. doi: 10.1093.
    PubMed     Abstract available


  183. WHITE JL, Grabowski MK, Rositch AF, Gravitt PE, et al
    Trends in adolescent human papillomavirus vaccination and parental hesitancy in the United States.
    J Infect Dis. 2023 Mar 3:jiad055. doi: 10.1093.
    PubMed     Abstract available


  184. SUN P, Balinsky CA, Jiang L, Jani V, et al
    Antibody Responses to the SARS-CoV-2 Ancestral Strain and Omicron Variants in Moderna mRNA-1273 Vaccinated Active-Duty U.S. Navy Sailors and Marines.
    J Infect Dis. 2023 Mar 1:jiad054. doi: 10.1093.
    PubMed     Abstract available


  185. RAADSEN MP, Dahlke C, Fathi A, Lamers MM, et al
    Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein.
    J Infect Dis. 2023 Mar 1:jiad052. doi: 10.1093.
    PubMed     Abstract available


  186. TILEY KS, Ratcliffe H, Voysey M, Jefferies K, et al
    Nasopharyngeal Carriage of Pneumococcus in Children in England up to 10 Years After 13-Valent Pneumococcal Conjugate Vaccine Introduction: Persistence of Serotypes 3 and 19A and Emergence of 7C.
    J Infect Dis. 2023;227:610-621.
    PubMed     Abstract available


    February 2023
  187. CORTESE MM, Taylor AW, Akinbami LJ, Thames-Allen A, et al
    Surveillance for multisystem inflammatory syndrome in U.S. children aged 5-11 years who received Pfizer-BioNTech COVID-19 vaccine, November 2021-March 2022.
    J Infect Dis. 2023 Feb 23:jiad051. doi: 10.1093.
    PubMed     Abstract available


  188. BOZIO CH, Butterfield KA, Briggs Hagen M, Grannis S, et al
    Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance.
    J Infect Dis. 2023 Feb 18:jiad040. doi: 10.1093.
    PubMed     Abstract available


  189. HUAPAYA JA, Higgins J, Kanth S, Demirkale C, et al
    Vaccination Ameliorates Cellular Inflammatory Responses in SARS-CoV-2 Breakthrough Infections.
    J Infect Dis. 2023 Feb 18:jiad045. doi: 10.1093.
    PubMed     Abstract available


  190. ALTHAUS T, Landier J, Zhu F, Raps H, et al
    The impact of SARS-CoV-2 vaccination and infection on neutralising antibodies: a nation-wide cross-sectional analysis.
    J Infect Dis. 2023 Feb 14:jiad030. doi: 10.1093.
    PubMed     Abstract available


  191. HITCHINGS MDT, Borgert BA, Shir A, Yang B, et al
    Dynamics of anti-influenza mucosal IgA over a season in a cohort of individuals living or working in a long-term care facility.
    J Infect Dis. 2023 Feb 6:jiad029. doi: 10.1093.
    PubMed     Abstract available


  192. DESANTIS SM, Yaseen A, Hao T, Leon-Novelo L, et al
    Incidence and predictors of breakthrough and severe breakthrough infections of SARS-CoV-2 after primary series vaccination in adults: A population-based survey of 22,575 participants.
    J Infect Dis. 2023 Feb 2:jiad020. doi: 10.1093.
    PubMed     Abstract available


  193. BEBIA Z, Reyes O, Jeanfreau R, Kantele A, et al
    Safety and immunogenicity of an investigational respiratory syncytial virus vaccine (RSVPreF3) in mothers and their infants: a phase 2 randomized trial.
    J Infect Dis. 2023 Feb 1:jiad024. doi: 10.1093.
    PubMed     Abstract available


    January 2023
  194. THOMPSON P, Parr JB, Boisson A, Razavi-Shearer D, et al
    Now is the Time to Scale Up Birth Dose Hepatitis Vaccine in Low and Middle-Income Countries.
    J Infect Dis. 2023 Jan 31:jiad026. doi: 10.1093.
    PubMed    


  195. ORTIZ JR, Bernstein DI, Hoft DF, Woods CW, et al
    A Multi-Center, Controlled Human Infection Study of Influenza A (H1N1)pdm09 in Healthy Adults.
    J Infect Dis. 2023 Jan 26:jiad021. doi: 10.1093.
    PubMed     Abstract available


  196. TENFORDE MW, Weber ZA, DeSilva MB, Stenehjem E, et al
    Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network.
    J Infect Dis. 2023 Jan 23:jiad015. doi: 10.1093.
    PubMed     Abstract available


  197. CHAMBERS C, Deeks SL, Sutradhar R, Cox J, et al
    Vaccine effectiveness against 12-month incident and persistent anal human papillomavirus infection among gay, bisexual, and other men who have sex with men.
    J Infect Dis. 2023 Jan 19:jiad005. doi: 10.1093.
    PubMed     Abstract available


  198. GRAY EJ, Cooper LV, Bandyopadhyay AS, Blake IM, et al
    The origins and risk factors for serotype-2 vaccine-derived poliovirus (VDPV2) emergences in Africa during 2016-2019.
    J Infect Dis. 2023 Jan 11:jiad004. doi: 10.1093.
    PubMed     Abstract available


  199. PEEBLES K, Arciuolo RJ, Romano AS, Sell J, et al
    Pfizer-BioNTech COVID-19 vaccine effectiveness against SARS-CoV-2 infection among long-term care facility staff with and without prior infection in New York City, January-June 2021.
    J Infect Dis. 2023 Jan 10:jiac448. doi: 10.1093.
    PubMed     Abstract available


    December 2022
  200. GREGG KA, Wang Y, Warfel J, Schoenfeld E, et al
    "Antigen Discovery for Next-Generation Pertussis Vaccines using Immunoproteomics and Transposon Directed Insertion Sequencing".
    J Infect Dis. 2022 Dec 28:jiac502. doi: 10.1093.
    PubMed     Abstract available


  201. NAKAGAMA Y, Candray K, Kaku N, Komase Y, et al
    Antibody avidity maturation, following recovery from infection or the booster vaccination, grants breadth in SARS-CoV-2 neutralizing capacity.
    J Infect Dis. 2022 Dec 22:jiac492. doi: 10.1093.
    PubMed     Abstract available


  202. DOUROS A, Ante Z, Suissa S, Brassard P, et al
    Common vaccines and the risk of incident dementia: a population-based cohort study.
    J Infect Dis. 2022 Dec 21:jiac484. doi: 10.1093.
    PubMed     Abstract available


  203. SALMON DA, Black S, Didierlaurent AM, Moulton LH, et al
    Commentary on "Common vaccines and the risk of dementia: a population-based cohort study": Science can be messy but eventually leads to truths.
    J Infect Dis. 2022 Dec 21:jiac487. doi: 10.1093.
    PubMed    


  204. MAYNARD-SMITH L, Derrick JP, Borrow R, Lucidarme J, et al
    Genome-Wide Association Studies Identify an Association of Transferrin Binding Protein B Variation and Invasive Serogroup Y Meningococcal Disease in Older Adults.
    J Infect Dis. 2022;226:2204-2214.
    PubMed     Abstract available


  205. REICHERZ F, Xu RY, Abu-Raya B, Majdoubi A, et al
    Waning Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019 Pandemic.
    J Infect Dis. 2022;226:2064-2068.
    PubMed     Abstract available


  206. DIEZ-DOMINGO J, Saez-Llorens X, Rodriguez-Weber MA, Epalza C, et al
    Safety and immunogenicity of a ChAd155-vectored RSV vaccine (ChAd155-RSV) in healthy RSV-seropositive children 12-23 months of age.
    J Infect Dis. 2022 Dec 9:jiac481. doi: 10.1093.
    PubMed     Abstract available


  207. ACOSTA CJ, Diaz C, Nordio F, Han HH, et al
    Persistence of Immunogenicity of a Purified Inactivated Zika Virus Vaccine Candidate in Healthy Adults: 2 Years of Follow-Up Compared With Natural Infection.
    J Infect Dis. 2022 Dec 9:jiac482. doi: 10.1093.
    PubMed     Abstract available



  208. Correction to: "Protection by Vaccines and Previous Infection Against the Omicron Variant of Severe Acute Respiratory Syndrome Coronavirus 2".
    J Infect Dis. 2022 Dec 8:jiac429. doi: 10.1093.
    PubMed    


  209. SHIODA K, Chen Y, Collins MH, Lopman BA, et al
    Population-Level Relative Effectiveness of the COVID-19 Vaccines and the Contribution of Naturally Acquired Immunity.
    J Infect Dis. 2022 Dec 7:jiac483. doi: 10.1093.
    PubMed     Abstract available


  210. NASCIMENTO EJM, Norwood B, Kpamegan E, Parker A, et al
    Antibodies Produced in Response to a Live-Attenuated Dengue Vaccine are Functional in Activating the Complement System.
    J Infect Dis. 2022 Dec 3:jiac476. doi: 10.1093.
    PubMed     Abstract available


  211. GREWAL R, Nguyen L, Buchan SA, Wilson SE, et al
    Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada.
    J Infect Dis. 2022 Dec 3:jiac468. doi: 10.1093.
    PubMed     Abstract available


    November 2022
  212. STIRRUP O, Krutikov M, Tut G, Palmer T, et al
    Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI).
    J Infect Dis. 2022;226:1877-1881.
    PubMed     Abstract available


  213. MONTO AS, Lauring AS, Martin ET
    SARS-CoV-2 Vaccine Strain Selection: Guidance from Influenza.
    J Infect Dis. 2022 Nov 25:jiac454. doi: 10.1093.
    PubMed     Abstract available


  214. VANNIER E, Richer LM, Dinh DM, Brisson D, et al
    Deployment of a reservoir-targeted vaccine against Borreliella burgdorferi reduces the prevalence of Babesia microti coinfection in Ixodes scapularis ticks.
    J Infect Dis. 2022 Nov 23:jiac462. doi: 10.1093.
    PubMed     Abstract available


  215. WANG X, Zein J, Ji X, Lin DY, et al
    Impact of Vaccination, Prior Infection and Therapy on Omicron Infection and Mortality.
    J Infect Dis. 2022 Nov 23:jiac460. doi: 10.1093.
    PubMed     Abstract available


  216. DESILVA MB, Mitchell PK, Klein NP, Dixon BE, et al
    Protection of 2 and 3 mRNA Vaccine Doses Against Severe Outcomes Among Adults Hospitalized with COVID-19 - VISION Network, August 2021 - March 2022.
    J Infect Dis. 2022 Nov 23:jiac458. doi: 10.1093.
    PubMed     Abstract available


  217. TOMETTEN I, Landmann S, Kantauskaite M, Lamberti J, et al
    Factors associated with vaccine-induced T cell immune responses against SARS-CoV-2 in kidney transplant recipients.
    J Infect Dis. 2022 Nov 21:jiac449. doi: 10.1093.
    PubMed     Abstract available


  218. ILCHMANN H, Samy N, Reichhardt D, Schmidt D, et al
    Single and 2-dose vaccinations with modified vaccinia Ankara-Bavarian Nordic(R) induce durable B cell memory responses comparable to replicating smallpox vaccines.
    J Infect Dis. 2022 Nov 21:jiac455. doi: 10.1093.
    PubMed     Abstract available


  219. LIND ML, Copin R, McCarthy S, Coppi A, et al
    Use of whole genome sequencing to estimate the contribution of immune evasion and waning immunity on decreasing COVID-19 vaccine effectiveness.
    J Infect Dis. 2022 Nov 21:jiac453. doi: 10.1093.
    PubMed     Abstract available


  220. JONGKEES MJ, Geers D, Hensley KS, Huisman W, et al
    Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination.
    J Infect Dis. 2022 Nov 19:jiac451. doi: 10.1093.
    PubMed     Abstract available


  221. EIDEN J, Fierro C, Schwartz H, Adams M, et al
    Intranasal M2SR (M2-deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies In Adults.
    J Infect Dis. 2022 Nov 9. pii: 6807529. doi: 10.1093.
    PubMed     Abstract available


  222. STIEH DJ, Barouch DH, Comeaux C, Sarnecki M, et al
    Safety and Immunogenicity of Ad26-vectored HIV Vaccine with Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-uninfected Adults: A Phase 1/2a Study.
    J Infect Dis. 2022 Nov 9. pii: 6812747. doi: 10.1093.
    PubMed     Abstract available


  223. JAGER M, Dichtl S, Bellmann-Weiler R, Reindl M, et al
    Serum neutralization against SARS-CoV-2 variants is heterogenic and depends on vaccination regimen.
    J Infect Dis. 2022 Nov 1. pii: 6783141. doi: 10.1093.
    PubMed     Abstract available


  224. KUO TY, Lien CE, Lin YJ, Lin MY, et al
    Hamsters Protected from SARS-CoV-2 Delta Variant Challenge after Two Doses of Adjuvanted SARS-CoV-2 Recombinant Spike Protein (S-2P) and One Dose of Beta S-2P.
    J Infect Dis. 2022;226:1562-1567.
    PubMed     Abstract available


  225. MIDDLETON BF, Danchin M, Jones MA, Leach AJ, et al
    Immunogenicity of a Third Scheduled Dose of Rotarix in Australian Indigenous Infants: A Phase IV, Double-blind, Randomized, Placebo-Controlled Clinical Trial.
    J Infect Dis. 2022;226:1537-1544.
    PubMed     Abstract available


    October 2022
  226. DE SILVA A, White L
    Immunogenicity of a live dengue vaccine (TAK-003).
    J Infect Dis. 2022 Oct 26. pii: 6774399. doi: 10.1093.
    PubMed    


  227. ROE MK, Perez MA, Hsiao HM, Lapp SA, et al
    An RSV live-attenuated vaccine candidate lacking G protein mucin domains is attenuated, immunogenic, and effective in preventing RSV in BALB/c mice.
    J Infect Dis. 2022 Oct 25. pii: 6770706. doi: 10.1093.
    PubMed     Abstract available


  228. LEUNG J, Dooling K, Marin M, Anderson TC, et al
    The Impact of Universal Varicella Vaccination on Herpes Zoster Incidence in the United States: Comparison of Birth Cohorts Preceding and Following Varicella Vaccination Program Launch.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  229. MARIN M, Leung J, Anderson TC, Lopez AS, et al
    Monitoring Varicella Vaccine Impact on Varicella Incidence in the United States: Surveillance Challenges and Changing Epidemiology, 1995-2019.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  230. WILLIS ED, Marko AM, Rasmussen SA, McGee M, et al
    Merck/Centers for Disease Control and Prevention Varicella Vaccine Pregnancy Registry: 19-Year Summary of Data From Inception Through Closure, 1995-2013.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  231. ARVIN AM
    Insights From Studies of the Genetics, Pathogenesis, and Immunogenicity of the Varicella Vaccine.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  232. MARIN M, Lopez AS, Melgar M, Dooling K, et al
    Decline in Severe Varicella Disease During the United States Varicella Vaccination Program: Hospitalizations and Deaths, 1990-2019.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  233. LEUNG J, Lopez AS, Marin M
    Changing Epidemiology of Varicella Outbreaks in the United States During the Varicella Vaccination Program, 1995-2019.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  234. DOLLARD S, Chen MH, Lindstrom S, Marin M, et al
    Diagnostic and Immunologic Testing for Varicella in the Era of High-Impact Varicella Vaccination: An Evolving Problem.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  235. DREES M, Weber DJ
    Prevention and Control of Nosocomial Varicella During the United States Varicella Vaccination Program Era.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  236. ELAM-EVANS LD, Valier MR, Fredua B, Zell E, et al
    Celebrating 25 Years of Varicella Vaccination Coverage for Children and Adolescents in the United States: A Success Story.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  237. ZHOU F, Leung J, Marin M, Dooling KL, et al
    Health and Economic Impact of the United States Varicella Vaccination Program, 1996-2020.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  238. MORO PL, Leung J, Marquez P, Kim Y, et al
    Safety Surveillance of Varicella Vaccines in the Vaccine Adverse Event Reporting System, United States, 2006-2020.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  239. MARIN M, Seward JF, Gershon AA
    25 Years of Varicella Vaccination in the United States.
    J Infect Dis. 2022;226.
    PubMed    


  240. SHAPIRO ED, Marin M
    The Effectiveness of Varicella Vaccine: 25 Years of Postlicensure Experience in the United States.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  241. DOOLING K, Marin M, Gershon AA
    Clinical Manifestations of Varicella: Disease Is Largely Forgotten, but It's Not Gone.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  242. ANDERSON M, Stec M, Gosha A, Mohammad T, et al
    Longitudinal SARS-CoV-2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid IgG.
    J Infect Dis. 2022 Oct 20. pii: 6764413. doi: 10.1093.
    PubMed     Abstract available


  243. LAAKE I, Skodvin SN, Blix K, Caspersen IH, et al
    Effectiveness of mRNA booster vaccination against mild, moderate, and severe COVID-19 caused by the Omicron variant in a large, population-based, Norwegian cohort.
    J Infect Dis. 2022 Oct 19. pii: 6763324. doi: 10.1093.
    PubMed     Abstract available


  244. STUART A, Virta M, Williams K, Seppa I, et al
    Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector RSV Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV Seropositive Children 12-24 Months.
    J Infect Dis. 2022 Oct 19. pii: 6763323. doi: 10.1093.
    PubMed     Abstract available


  245. AGALLOU M, Koutsoni OS, Michail M, Zisimopoulou P, et al
    Antibody and T cell subsets analysis unveils an immune profile heterogeneity mediating long-term responses in individuals vaccinated against SARS-CoV-2.
    J Infect Dis. 2022 Oct 19. pii: 6763327. doi: 10.1093.
    PubMed     Abstract available


  246. BADIZADEGAN K, Kalkowska DA, Thompson KM
    Polio by the Numbers-A Global Perspective.
    J Infect Dis. 2022;226:1309-1318.
    PubMed     Abstract available


  247. SHOVER CL, Rosen A, Mata J, Robie B, et al
    Engaging Same-Day Peer Ambassadors to Increase Coronavirus Disease 2019 Vaccination Among People Experiencing Unsheltered Homelessness in Los Angeles County: A Hybrid Feasibility-Evaluation Study.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  248. GIBSON C, Schumann C, Neuschel K, McBride JA, et al
    COVID-19 Vaccination Coverage Among People Experiencing Homelessness in a Highly Vaccinated Midwest County-Dane County, Wisconsin, 2021.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  249. RUDMANN KC, Brown NE, Rubis AB, Burns M, et al
    Invasive Meningococcal Disease Among People Experiencing Homelessness-United States, 2016-2019.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  250. BENET S, Blanch-Lombarte O, Ainsua-Enrich E, Pedreno-Lopez N, et al
    Limited humoral and specific T-cell responses after SARS-CoV-2 vaccination in PLWH with poor immune reconstitution.
    J Infect Dis. 2022 Oct 6. pii: 6749018. doi: 10.1093.
    PubMed     Abstract available


  251. CHAN CEZ, Wong SKK, Yazid NBM, Ng OT, et al
    Residual humoral immunity sustained over decades in a cohort of vaccinia-vaccinated individuals.
    J Infect Dis. 2022 Oct 6. pii: 6749013. doi: 10.1093.
    PubMed     Abstract available


  252. ASAMOAH-BOAHENG M, Goldfarb DM, Karim ME, O'Brien SF, et al
    The relationship between anti-spike SARS-CoV-2 antibody levels and risk of breakthrough COVID-19 among fully vaccinated adults.
    J Infect Dis. 2022 Oct 5. pii: 6748952. doi: 10.1093.
    PubMed     Abstract available


    September 2022
  253. FURUKAWA K, Kurahashi Y, Ishimaru H, Nishimura M, et al
    The number of COVID-19 vaccine doses and severe clinical outcomes in older patients infected with a SARS-CoV-2 Omicron variant.
    J Infect Dis. 2022 Sep 26. pii: 6717967. doi: 10.1093.
    PubMed    


  254. AMANO M, Otsu S, Ichikawa Y, Higashi-Kuwata N, et al
    Restoration of neutralization activity against Omicrons BA.2 and BA.5 in older adults and individuals with risk factors following the 4th-dose of SARS-CoV-2 BNT162b2 vaccine.
    J Infect Dis. 2022 Sep 22. pii: 6711120. doi: 10.1093.
    PubMed    


  255. LUNA-MUSCHI A, Noguera SV, Borges IC, De Paula AV, et al
    Characterization of SARS-CoV-2 Omicron variant shedding and predictors of viral culture positivity on vaccinated healthcare workers with mild COVID-19.
    J Infect Dis. 2022 Sep 22. pii: 6711076. doi: 10.1093.
    PubMed     Abstract available


  256. BRAZER N, Morris MK, Servellita V, Anglin K, et al
    Neutralizing immunity induced against the Omicron BA.1 and BA.2 variants in vaccine breakthrough infections.
    J Infect Dis. 2022 Sep 22. pii: 6711075. doi: 10.1093.
    PubMed     Abstract available


  257. KLUGMAN KP, Rodgers GL
    Pneumococcal carriage and sero-epidemiology studies to measure current and future pneumococcal conjugate vaccine effectiveness.
    J Infect Dis. 2022 Sep 21. pii: 6710232. doi: 10.1093.
    PubMed    


  258. ROSSLER A, Kimpel J, Fleischer V, Huber S, et al
    Regimen of COVID-19 vaccination influences extent and kinetics of antibody avidity.
    J Infect Dis. 2022 Sep 16. pii: 6701886. doi: 10.1093.
    PubMed     Abstract available


  259. COWLING BJ, Cheng SMS, Martin-Sanchez M, Au NYM, et al
    Slow waning of antibodies following a third dose of BNT162b2 in adults who had previously received two doses of inactivated vaccine.
    J Infect Dis. 2022 Sep 15. pii: 6701635. doi: 10.1093.
    PubMed     Abstract available


  260. KU JH, Levin MJ, Luo Y, Florea A, et al
    Risk of Severe Coronavirus Disease 2019 Disease in Individuals With Down Syndrome: A Matched Cohort Study From a Large, Integrated Health Care System.
    J Infect Dis. 2022;226:757-765.
    PubMed     Abstract available


  261. GOLDSTEIN N, Bockstal V, Bart S, Luhn K, et al
    Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study.
    J Infect Dis. 2022;226:595-607.
    PubMed     Abstract available


  262. YANG B, Wong IOL, Xiao J, Tsang TK, et al
    Effectiveness of CoronaVac and BNT162b2 vaccine against SARS-CoV-2 Omicron BA.2 infections in Hong Kong.
    J Infect Dis. 2022 Sep 2. pii: 6687716. doi: 10.1093.
    PubMed     Abstract available


    August 2022
  263. SHAW AG, Cooper LV, Gumede N, Bandyopadhyay AS, et al
    Time Taken to Detect and Respond to Polio Outbreaks in Africa and the Potential Impact of Direct Molecular Detection and Nanopore Sequencing.
    J Infect Dis. 2022;226:453-462.
    PubMed     Abstract available


  264. SADOFF J, De Paepe E, DeVincenzo J, Gymnopoulou E, et al
    Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.
    J Infect Dis. 2022;226:396-406.
    PubMed     Abstract available


  265. BEALL B, Chochua S, Li Z, Tran T, et al
    Invasive Pneumococcal Disease Clusters Disproportionally Impact Persons Experiencing Homelessness, Injecting Drug Users, and the Western United States.
    J Infect Dis. 2022;226:332-341.
    PubMed     Abstract available


  266. TORNELL A, Grauers Wiktorin H, Ringlander J, Arabpour M, et al
    Rapid Cytokine Release Assays for Analysis of Severe Acute Respiratory Syndrome Coronavirus 2-Specific T Cells in Whole Blood.
    J Infect Dis. 2022;226:208-216.
    PubMed     Abstract available


  267. QUACH HQ, Chen J, Monroe JM, Ratishvili T, et al
    The influence of sex, BMI, and age on cellular and humoral immune responses against measles after a 3rd dose of MMR vaccine.
    J Infect Dis. 2022 Aug 22. pii: 6673362. doi: 10.1093.
    PubMed     Abstract available


  268. MIYAKAWA K, Kato H, Ohtake N, Stanleyraj Jeremiah S, et al
    Enhancement of humoral and cellular immunity against SARS-CoV-2 by a third dose of BNT162b2 vaccine in Japanese healthcare workers.
    J Infect Dis. 2022 Aug 18. pii: 6670905. doi: 10.1093.
    PubMed     Abstract available


  269. GOMEZ GB, Nelson CB, Rizzo C, Shepard DS, et al
    Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States.
    J Infect Dis. 2022;226.
    PubMed     Abstract available


  270. HOA LNM, Sullivan SG, Mai LQ, Khvorov A, et al
    Influenza A(H1N1)pdm09 But Not A(H3N2) Virus Infection Induces Durable Seroprotection: Results From the Ha Nam Cohort.
    J Infect Dis. 2022;226:59-69.
    PubMed     Abstract available


  271. CRAVENS M, Alugupalli AS, Sandilya VK, McGeady SJ, et al
    The IgM response to pneumococcal polysaccharide vaccine is sufficient for conferring immunity.
    J Infect Dis. 2022 Aug 6. pii: 6657690. doi: 10.1093.
    PubMed     Abstract available


  272. GREBE E, Yu EA, Bravo MD, Welte A, et al
    COVID-19 vaccine effectiveness against SARS-CoV-2 infection in the United States prior to the Delta and Omicron-associated surges: a retrospective cohort study of repeat blood donors.
    J Infect Dis. 2022 Aug 3. pii: 6654836. doi: 10.1093.
    PubMed     Abstract available


    July 2022
  273. VIVALDI G, Jolliffe DA, Faustini S, Shields AM, et al
    Correlation between post-vaccination anti-Spike antibody titres and protection against breakthrough SARS-CoV-2 infection: a population-based longitudinal study.
    J Infect Dis. 2022 Jul 30. pii: 6652292. doi: 10.1093.
    PubMed     Abstract available


  274. LEROUX-ROELS I, Davis MG, Steenackers K, Essink B, et al
    Safety and immunogenicity of a respiratory syncytial virus prefusion F (RSVPreF3) candidate vaccine in older adults: phase I/II randomized clinical trial.
    J Infect Dis. 2022 Jul 29. pii: 6651941. doi: 10.1093.
    PubMed     Abstract available


  275. KNOLL MD, Bennett JC, Yang Y, Quesada MG, et al
    Challenges inferring pneumococcal conjugate vaccine impact from bacterial surveillance data.
    J Infect Dis. 2022 Jul 28. pii: 6650942. doi: 10.1093.
    PubMed    


  276. CHU WM, Lee YH, Cheng-Chung Wei J, Lee YH, et al
    Comment on Recombinant Adjuvanted Zoster Vaccine and Reduced Risk of Coronavirus Disease 2019 Diagnosis and Hospitalization in Older Adults.
    J Infect Dis. 2022 Jul 26. pii: 6649924. doi: 10.1093.
    PubMed    


  277. CRISTINA CASSETTI M, Pierson TC, Jean Patterson L, Bok K, et al
    Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness.
    J Infect Dis. 2022 Jul 25. pii: 6649664. doi: 10.1093.
    PubMed     Abstract available


  278. MAHANT A, Guerguis S, Blevins TP, Cheshenko N, et al
    Herpes Simplex Virus Glycoprotein D Antibodies Fail to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.
    J Infect Dis. 2022 Jul 14. pii: 6644507. doi: 10.1093.
    PubMed     Abstract available


  279. BRADFUTE S, Mertz G
    Immune responses to herpes simplex virus infection: implications for vaccine development.
    J Infect Dis. 2022 Jul 8. pii: 6633820. doi: 10.1093.
    PubMed    


  280. WAGNER AL, Sanchez N, Kubale J, Kuan G, et al
    Single dose vaccination among infants and toddlers provides modest protection against influenza illness which wanes after 5 months.
    J Infect Dis. 2022 Jul 7. pii: 6633354. doi: 10.1093.
    PubMed     Abstract available


  281. COSSU MV, Mileto D, Giacomelli A, Oreni L, et al
    Does the co-morbidity burden contribute to suboptimal immunological responses to COVID-19 vaccination in people living with HIV?
    J Infect Dis. 2022 Jul 7. pii: 6633353. doi: 10.1093.
    PubMed    


  282. ASSAWAKOSRI S, Suntronwong N, Yorsaeng R, Kanokudom S, et al
    Breakthrough infection by SARS-CoV-2 Delta and Omicron variants elicited immune response comparable to mRNA booster vaccination.
    J Infect Dis. 2022 Jul 5. pii: 6631219. doi: 10.1093.
    PubMed    


  283. REN Z, Sun R, Cui G, Wang H, et al
    Effects of Inactivated Vaccination on Humoral Immune Responses in Patients Infected with Delta or Omicron Variants.
    J Infect Dis. 2022 Jul 5. pii: 6631218. doi: 10.1093.
    PubMed    


  284. NYOMBAYIRE J, Ingabire R, Magod B, Mazzei A, et al
    Monitoring of adverse events in recipients of the 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
    J Infect Dis. 2022 Jul 1. pii: 6625827. doi: 10.1093.
    PubMed     Abstract available


    June 2022
  285. DEMASO CR, Karwal L, Zahralban-Steele M, Dominguez D, et al
    Specificity and Breadth of the Neutralizing Antibody Response to a Live Attenuated Tetravalent Dengue Vaccine.
    J Infect Dis. 2022 Jun 30. pii: 6623496. doi: 10.1093.
    PubMed     Abstract available


  286. VENCALEK O, Beran J, Furst T, Kratka Z, et al
    Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
    J Infect Dis. 2022 Jun 28. pii: 6619238. doi: 10.1093.
    PubMed    


  287. LLIBRE JM, Revollo B, Aguilar S, Calomarde-Gomez C, et al
    Protection against severe clinical outcomes with adenovirus or mRNA SARS-CoV-2 vaccines in patients hospitalized with Covid-19.
    J Infect Dis. 2022 Jun 28. pii: 6619237. doi: 10.1093.
    PubMed    


  288. MOY JN, Anderson M, Shen X, Fu J, et al
    Neutralizing Antibody Activity to SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) After One and Two Doses of BNT162b2 Vaccine in Infection-Naive and Previously-Infected Individuals.
    J Infect Dis. 2022 Jun 27. pii: 6618640. doi: 10.1093.
    PubMed     Abstract available


  289. AMJADI MF, Adyniec RR, Gupta S, Bashar SJ, et al
    Anti-membrane antibodies persist at least one year and discriminate between past COVID-19 infection and vaccination.
    J Infect Dis. 2022 Jun 27. pii: 6618636. doi: 10.1093.
    PubMed     Abstract available


  290. MOODIE Z, Dintwe O, Sawant S, Grove D, et al
    Analysis of the HVTN 702 Phase 2b-3 HIV-1 vaccine trial in South Africa assessing RV144 antibody and T-cell correlates of HIV-1 acquisition risk.
    J Infect Dis. 2022 Jun 27. pii: 6618597. doi: 10.1093.
    PubMed     Abstract available


  291. STRENG BMM, Bont M, Delemarre EM, Binnendijk RS, et al
    Decreased antibody response after SARS-CoV-2 vaccination in patients with Down Syndrome.
    J Infect Dis. 2022 Jun 24. pii: 6617441. doi: 10.1093.
    PubMed     Abstract available


  292. CUNNINGHAM CK, Karron RA, Muresan P, Kelly MS, et al
    Evaluation of Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccines RSV/DeltaNS2/Delta1313/I1314L and RSV/276 in RSV Seronegative Children.
    J Infect Dis. 2022 Jun 23. pii: 6613410. doi: 10.1093.
    PubMed     Abstract available


  293. VARESE A, Mazzitelli B, Diaz FE, Kjolhede MV, et al
    Omicron breakthrough infection after heterologous prime-boost vaccination induces a vigorous antibody response.
    J Infect Dis. 2022 Jun 20. pii: 6611839. doi: 10.1093.
    PubMed     Abstract available


  294. GUIRAKHOO F, Wang S, Wang CY, Kuo HK, et al
    High neutralizing antibody levels against SARS-CoV-2 Omicron BA.1 and BA.2 after UB-612 vaccine booster.
    J Infect Dis. 2022 Jun 20. pii: 6611838. doi: 10.1093.
    PubMed     Abstract available


  295. LEMASTER C, Geanes ES, Fraley ER, Selvarangan R, et al
    Vaccination after SARS-CoV-2 infection increased antibody avidity against the Omicron variant compared to vaccination alone.
    J Infect Dis. 2022 Jun 18. pii: 6609994. doi: 10.1093.
    PubMed     Abstract available


  296. DONATO CM, Roczo-Farkas S, Kirkwood CD, Barnes GL, et al
    Rotavirus Disease and Genotype Diversity in Older Children and Adults in Australia.
    J Infect Dis. 2022;225:2116-2126.
    PubMed     Abstract available


  297. SIEDNER MJ, Alba C, Fitzmaurice KP, Gilbert RF, et al
    Cost-effectiveness of COVID-19 vaccination in low- and middle-income countries.
    J Infect Dis. 2022 Jun 13. pii: 6606162. doi: 10.1093.
    PubMed     Abstract available


  298. JACOBSON JM
    Immune Responses to SARS-CoV-2 Vaccination in People With HIV: A Tale of Two Pandemics.
    J Infect Dis. 2022 Jun 7. pii: 6603522. doi: 10.1093.
    PubMed    


  299. LAPOINTE HR, Mwimanzi F, Cheung PK, Sang Y, et al
    People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses.
    J Infect Dis. 2022 Jun 7. pii: 6603521. doi: 10.1093.
    PubMed     Abstract available


  300. STORCH GA
    Respiratory syncytial virus (RSV) around the globe: data to help guide wise use of vaccines and anti-virals.
    J Infect Dis. 2022 Jun 6. pii: 6603523. doi: 10.1093.
    PubMed    


    May 2022
  301. ROSTAD CA, Chen X, Sun HY, Hussaini L, et al
    Functional antibody responses to SARS-CoV-2 variants in children with COVID-19, MIS-C, and after two doses of BNT162b2 vaccination.
    J Infect Dis. 2022 May 26. pii: 6593309. doi: 10.1093.
    PubMed     Abstract available


  302. OSTER G, Bornheimer R, Ottino K
    Letter to the Editor in Response to Hall EW, Weng MK, Harris AM, et al. Assessing the Cost-Utility of Universal Hepatitis B Vaccination Among Adults.
    J Infect Dis. 2022 May 26. pii: 6593317. doi: 10.1093.
    PubMed    


  303. NALIN D
    Cholera control requires reducing mortality along with vaccination programs.
    J Infect Dis. 2022 May 18. pii: 6588066. doi: 10.1093.
    PubMed    


  304. AMANO M, Maeda K, Tsuchiya K, Shimada S, et al
    Third-dose BNT162b2 vaccination elicits markedly high-level SARS-CoV-2-neutralizing antibodies in vaccinees who poorly responded to second dose in Japan.
    J Infect Dis. 2022 May 17. pii: 6587098. doi: 10.1093.
    PubMed    


  305. AZIZ AB, Verma H, Jeyaseelan V, Md Y, et al
    One full or two fractional doses of inactivated poliovirus vaccine for catch-up vaccination in older infants: A randomized clinical trial in Bangladesh.
    J Infect Dis. 2022 May 16. pii: 6586252. doi: 10.1093.
    PubMed     Abstract available


  306. FAUSTHER-BOVENDO H, Qiu X, Babuadze GG, Azizi H, et al
    Transient Liver Damage and Hemolysis Are Associated With an Inhibition of Ebola Virus Glycoprotein-Specific Antibody Response and Lymphopenia.
    J Infect Dis. 2022;225:1852-1855.
    PubMed     Abstract available


  307. BABER J, Arya M, Moodley Y, Jaques A, et al
    A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older Adults.
    J Infect Dis. 2022 May 11. pii: 6583554. doi: 10.1093.
    PubMed     Abstract available


  308. MWIMANZI F, Lapointe HR, Cheung PK, Sang Y, et al
    Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose.
    J Infect Dis. 2022 May 11. pii: 6583561. doi: 10.1093.
    PubMed     Abstract available


  309. EL SAHLY HM, Baden LR, Essink B, Montefiori D, et al
    Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 COVE Trial.
    J Infect Dis. 2022 May 10. pii: 6583011. doi: 10.1093.
    PubMed     Abstract available


  310. MUHR LSA, Eklund C, Lagheden C, Eriksson T, et al
    Head-to-head comparison of bi- and nonavalent human papillomavirus vaccine-induced antibody responses.
    J Infect Dis. 2022 May 10. pii: 6582940. doi: 10.1093.
    PubMed     Abstract available


  311. LIU B, Stepien S, Pye V, Law C, et al
    High attack rate of SARS-CoV-2 B.1.1.529 among two-dose vaccinated populations in two indoor entertainment setting outbreaks.
    J Infect Dis. 2022 May 7. pii: 6582820. doi: 10.1093.
    PubMed     Abstract available


  312. KURAHASHI Y, Furukawa K, Sutandhio S, Tjan LH, et al
    Cross-neutralizing activity against Omicron could be obtained in SARS-CoV-2 convalescent patients who received two doses of mRNA vaccination.
    J Infect Dis. 2022 May 5. pii: 6580685. doi: 10.1093.
    PubMed     Abstract available


  313. MITSI E, McLenaghan D, Wolf AS, Jones S, et al
    Thirteen-Valent Pneumococcal Conjugate Vaccine-Induced Immunoglobulin G (IgG) Responses in Serum Associated With Serotype-Specific IgG in the Lung.
    J Infect Dis. 2022;225:1626-1631.
    PubMed     Abstract available


  314. SIRIVICHAYAKUL C, Barranco-Santana EA, Rivera IE, Kilbury J, et al
    Long-term Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Children and Adults: A Randomized, Placebo-Controlled, Phase 2 Study.
    J Infect Dis. 2022;225:1513-1520.
    PubMed     Abstract available


    April 2022
  315. SMID M, Berec L, Pribylova L, Majek O, et al
    Protection by vaccines and previous infection against the Omicron variant of SARS-CoV-2.
    J Infect Dis. 2022 Apr 28. pii: 6575414. doi: 10.1093.
    PubMed     Abstract available


  316. TJAN LH, Furukawa K, Kurahashi Y, Sutandhio S, et al
    As well as Omicron BA.1, high neutralizing activity against Omicron BA.2 can be induced by COVID-19 mRNA booster vaccination.
    J Infect Dis. 2022 Apr 28. pii: 6575227. doi: 10.1093.
    PubMed    


  317. BAJEMA KL, Gierke R, Farley MM, Schaffner W, et al
    Impact of Pneumococcal Conjugate Vaccines on Antibiotic-Nonsusceptible Invasive Pneumococcal Disease in the United States.
    J Infect Dis. 2022 Apr 28. pii: 6575225. doi: 10.1093.
    PubMed     Abstract available


  318. ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Puenpa J, et al
    Omicron BA.1, BA.2 and COVID-19 booster vaccination.
    J Infect Dis. 2022 Apr 27. pii: 6575160. doi: 10.1093.
    PubMed    


  319. OKUDA M, Sakai-Tagawa Y, Koga M, Koibuchi T, et al
    Immunological correlates of prevention of the onset of seasonal H3N2 influenza.
    J Infect Dis. 2022 Apr 27. pii: 6574940. doi: 10.1093.
    PubMed     Abstract available


  320. LIN DY, Zeng D, Gu Y, Krause PR, et al
    Reliably Assessing Duration of Protection for COVID-19 Vaccines.
    J Infect Dis. 2022 Apr 21. pii: 6571630. doi: 10.1093.
    PubMed     Abstract available


  321. SKOWRONSKI DM, Leir S, Sabaiduc S, Chambers C, et al
    Influenza Vaccine Effectiveness by A(H3N2) Phylogenetic Subcluster and Prior Vaccination History: 2016-2017 and 2017-2018 Epidemics in Canada.
    J Infect Dis. 2022;225:1387-1398.
    PubMed     Abstract available


  322. BROKAW A, Nguyen S, Quach P, Orvis A, et al
    A recombinant alpha-like protein subunit vaccine (GBS-NN) provides protection in murine models of Group B Streptococcus infection.
    J Infect Dis. 2022 Apr 16. pii: 6569354. doi: 10.1093.
    PubMed     Abstract available


  323. ZHU KL, Gao HX, Yao L, Rong J, et al
    Delta infection following vaccination elicits potent neutralizing immunity against the SARS-CoV-2 Omicron.
    J Infect Dis. 2022 Apr 16. pii: 6569353. doi: 10.1093.
    PubMed     Abstract available


  324. LE GARS M, Sadoff J, Struyf F, Heerwegh D, et al
    Impact of preexisting anti-Ad26 humoral immunity on immunogenicity of the Ad26.COV2.S COVID-19 vaccine.
    J Infect Dis. 2022 Apr 16. pii: 6569363. doi: 10.1093.
    PubMed     Abstract available


  325. BOLOTIN S, Osman S, Hughes SL, Ariyarajah A, et al
    In Elimination Settings, Measles Antibodies Wane Following Vaccination but Not Following Infection - A Systematic Review and Meta-Analysis.
    J Infect Dis. 2022 Apr 13. pii: 6568034. doi: 10.1093.
    PubMed     Abstract available


  326. PERMAR SR, Kaur A, Fruh K
    De-risking human cytomegalovirus vaccine clinical development in relevant preclinical models.
    J Infect Dis. 2022 Apr 13. pii: 6567687. doi: 10.1093.
    PubMed    


  327. LI J, Wellnitz S, Chi XS, Yue Y, et al
    Horizontal transmission of cytomegalovirus in a rhesus model despite high-level, vaccine-elicited neutralizing antibody and T cell responses.
    J Infect Dis. 2022 Apr 12. pii: 6567520. doi: 10.1093.
    PubMed     Abstract available


  328. KWON JH, Tenforde MW, Gaglani M, Talbot HK, et al
    mRNA Vaccine Effectiveness Against COVID-19 Hospitalization Among Solid Organ Transplant Recipients.
    J Infect Dis. 2022 Apr 6. pii: 6564370. doi: 10.1093.
    PubMed     Abstract available


  329. XIONG W, Tsang TK, Perera RAPM, Leung NHL, et al
    Biphasic waning of hemagglutination inhibition antibody titers after influenza vaccination in children.
    J Infect Dis. 2022 Apr 5. pii: 6563665. doi: 10.1093.
    PubMed     Abstract available


  330. CARR OJJ, Vilivong K, Bounvilay L, Dunne EM, et al
    Nasopharyngeal Pneumococcal Colonization Density Is Associated With Severe Pneumonia in Young Children in the Lao People's Democratic Republic.
    J Infect Dis. 2022;225:1266-1273.
    PubMed     Abstract available


    March 2022
  331. ITSKO M, Topaz N, Ousmane S, Popoola M, et al
    Enhancing meningococcal genomic surveillance in the meningitis belt using high-resolution culture-free whole genome sequencing.
    J Infect Dis. 2022 Mar 24. pii: 6553907. doi: 10.1093.
    PubMed     Abstract available


  332. MARON JS, Conroy M, Naranbai V, Samarakoon U, et al
    Differential SARS-CoV-2 Antibody Profiles after Allergic Reactions to mRNA COVID-19 Vaccine.
    J Infect Dis. 2022 Mar 23. pii: 6553054. doi: 10.1093.
    PubMed     Abstract available


  333. RIEKE GJ, van Bremen K, Bischoff J, To Vinh M, et al
    Induction of NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 after natural infection is more potent than after vaccination.
    J Infect Dis. 2022 Mar 22. pii: 6552258. doi: 10.1093.
    PubMed     Abstract available


  334. LEWNARD JA, Bruxvoort KJ, Hong VX, Grant LR, et al
    Effectiveness of pneumococcal conjugate vaccination against virus-associated lower respiratory tract infection among adults: a case-control study.
    J Infect Dis. 2022 Mar 22. pii: 6552253. doi: 10.1093.
    PubMed     Abstract available


  335. LI X, Bilcke J, Vazquez Fernandez L, Bont L, et al
    Cost-effectiveness of Respiratory Syncytial Virus Disease Prevention Strategies: Maternal Vaccine Versus Seasonal or Year-Round Monoclonal Antibody Program in Norwegian Children.
    J Infect Dis. 2022 Mar 16. pii: 6549175. doi: 10.1093.
    PubMed     Abstract available


  336. ROHRIG A, Eyal N
    The Ethics of Human Challenge Trials Using Emerging Severe Acute Respiratory Syndrome 2 Variants.
    J Infect Dis. 2022;225:934-937.
    PubMed     Abstract available


  337. ASSAWAKOSRI S, Kanokudom S, Suntronwong N, Auphimai C, et al
    Neutralizing Activities against the Omicron Variant after a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination.
    J Infect Dis. 2022 Mar 10. pii: 6546425. doi: 10.1093.
    PubMed     Abstract available


  338. HALL EW, Weng MK, Harris AM, Schillie S, et al
    Assessing the cost-utility of universal hepatitis B vaccination among adults.
    J Infect Dis. 2022 Mar 9. pii: 6545195. doi: 10.1093.
    PubMed     Abstract available


  339. SANTONJA I, Stiasny K, Essl A, Heinz FX, et al
    Tick-borne encephalitis in vaccinated patients: a retrospective case-control study and analysis of vaccination field effectiveness in Austria from 2000 to 2018.
    J Infect Dis. 2022 Mar 2. pii: 6541329. doi: 10.1093.
    PubMed     Abstract available


    February 2022
  340. MORITZKY SA, Richards KA, Glover MA, Krammer F, et al
    The negative effect of pre-existing immunity on influenza vaccine responses transcends the impact of vaccine formulation type and vaccination history.
    J Infect Dis. 2022 Feb 24. pii: 6535476. doi: 10.1093.
    PubMed     Abstract available


  341. BELSHE RB, Blevins TP, Yu Y, Nethington AE, et al
    Neutralizing Antibody Kinetics and Immune Protection Against HSV-1 Genital Disease in Vaccinated Women.
    J Infect Dis. 2022 Feb 24. pii: 6535411. doi: 10.1093.
    PubMed     Abstract available


  342. LENTSCHER AJ, McAllister N, Griswold KA, Martin JL, et al
    Chikungunya virus vaccine candidate incorporating synergistic mutations is attenuated and protects against virulent virus challenge.
    J Infect Dis. 2022 Feb 23. pii: 6535121. doi: 10.1093.
    PubMed     Abstract available


  343. BURNETT E, Parashar UD, Winn A, Tate JE, et al
    Trends in rotavirus laboratory detections and internet search volume before and after rotavirus vaccine introduction and in the context of the COVID-19 pandemic-- United States 2000-2021.
    J Infect Dis. 2022 Feb 20. pii: 6532606. doi: 10.1093.
    PubMed     Abstract available


  344. HARALAMBIEVA IH, Monroe JM, Ovsyannikova IG, Grill DE, et al
    Distinct Homologous and Variant-Specific Memory B-Cell and Antibody Response Over Time after SARS-CoV-2 mRNA Vaccination.
    J Infect Dis. 2022 Feb 8. pii: 6524526. doi: 10.1093.
    PubMed     Abstract available


  345. KIM N, Shin S, Minn D, Park S, et al
    SARS-CoV-2 Infectivity and Antibody Titer Reduction for 6 Months After Second Dose of BNT162b2 mRNA Vaccine in Healthcare Workers: A Prospective Cohort Study.
    J Infect Dis. 2022 Feb 1. pii: 6519374. doi: 10.1093.
    PubMed     Abstract available


  346. RYAN KA, Schewe KE, Crowe J, Fotheringham SA, et al
    Sequential Delivery of Live Attenuated Influenza Vaccine and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in the Ferret Model Can Reduce SARS-CoV-2 Shedding and Does Not Result in Enhanced Lung Pathology.
    J Infect Dis. 2022;225:404-412.
    PubMed     Abstract available


    January 2022
  347. SPENGLER JR, Kainulainen MH, Welch SR, Coleman-McCray JAD, et al
    Lassa virus replicon particle vaccine protects strain 13/N guinea pigs against challenge with geographically and genetically diverse viral strains.
    J Infect Dis. 2022 Jan 31. pii: 6517689. doi: 10.1093.
    PubMed     Abstract available


  348. SKOWRONSKI DM, Setayeshgar S, Zou M, Prystajecky N, et al
    Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including variants of concern: test-negative design, British Columbia, Canada.
    J Infect Dis. 2022 Jan 27. pii: 6515934. doi: 10.1093.
    PubMed     Abstract available


  349. KRAYNYAK KA, Blackwood E, Agnes J, Tebas P, et al
    SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
    J Infect Dis. 2022 Jan 25. pii: 6515374. doi: 10.1093.
    PubMed     Abstract available


  350. GUAN M, Johannesen E, Tang CY, Hsu AL, et al
    Intrauterine fetal demise in the third trimester of pregnancy associated with mild infection with the SARS-CoV-2 Delta variant without protection from vaccination.
    J Infect Dis. 2022 Jan 13. pii: 6506263. doi: 10.1093.
    PubMed     Abstract available


  351. KRISTENSEN JH, Hasselbalch RB, Pries-Heje M, Nielsen PB, et al
    Effect of influenza vaccination on risk of COVID-19 - A prospective cohort study of 46,000 health care workers.
    J Infect Dis. 2022 Jan 5. pii: 6497955. doi: 10.1093.
    PubMed     Abstract available


  352. CHU VT, Simon E, Lu X, Rockwell P, et al
    Outbreak of Acute Respiratory Illness Associated With Human Adenovirus Type 4 at the United States Coast Guard Academy, 2019.
    J Infect Dis. 2022;225:55-64.
    PubMed     Abstract available


    December 2021
  353. LEWIS LA, Gulati S, Zelek WM, Morgan BP, et al
    Efficacy of an experimental gonococcal lipooligosaccharide mimitope vaccine requires terminal complement.
    J Infect Dis. 2021 Dec 31. pii: 6491069. doi: 10.1093.
    PubMed     Abstract available


  354. LUCZKOWIAK J, Labiod N, Rivas G, Rolo M, et al
    Neutralizing response against SARS-CoV-2 variants 8 months after BNT162b2 vaccination in naive and COVID-19 convalescent individuals.
    J Infect Dis. 2021 Dec 28. pii: 6486499. doi: 10.1093.
    PubMed     Abstract available


  355. BRUXVOORT KJ, Ackerson B, Sy LS, Bhavsar A, et al
    Recombinant adjuvanted zoster vaccine and reduced risk of COVID-19 diagnosis and hospitalization in older adults.
    J Infect Dis. 2021 Dec 28. pii: 6486498. doi: 10.1093.
    PubMed     Abstract available


  356. LIU J, Huang B, Li G, Chang X, et al
    Immunogenicity and Safety of a Three-Dose Regimen of a SARS-CoV-2 Inactivated Vaccine in Adults: A Randomized, Double-blind, Placebo-controlled Phase 2 Trial.
    J Infect Dis. 2021 Dec 27. pii: 6484920. doi: 10.1093.
    PubMed     Abstract available


  357. ABARA WE, Gee J, Delorey M, Tun Y, et al
    Expected Rates of Select Adverse Events following Immunization for COVID-19 Vaccine Safety Monitoring.
    J Infect Dis. 2021 Dec 27. pii: 6484617. doi: 10.1093.
    PubMed     Abstract available


  358. KIM SS, Naioti EA, Halasa NB, Stewart LS, et al
    Vaccine Effectiveness against Influenza Hospitalization and Emergency Department Visits in Two A(H3N2) Dominant Influenza Seasons among Children <18 Years Old, New Vaccine Surveillance Network 2016-17 and 2017-18.
    J Infect Dis. 2021 Dec 24. pii: 6482612. doi: 10.1093.
    PubMed     Abstract available


  359. PHIJFFER EWEM, Bont LJ
    Are we ready for maternal RSV vaccination?
    J Infect Dis. 2021 Dec 21. pii: 6472740. doi: 10.1093.
    PubMed    


  360. LEWIS NM, Naioti EA, Self WH, Ginde AA, et al
    Effectiveness of mRNA vaccines in preventing COVID-19 hospitalization by age and burden of chronic medical conditions among immunocompetent US adults, March-August 2021.
    J Infect Dis. 2021 Dec 21. pii: 6472998. doi: 10.1093.
    PubMed     Abstract available


  361. WALSH EE, Falsey AR, Scott DA, Gurtman A, et al
    A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine.
    J Infect Dis. 2021 Dec 21. pii: 6472747. doi: 10.1093.
    PubMed     Abstract available


  362. FALSEY AR, Walsh EE, Scott DA, Gurtman A, et al
    Phase 1/2 Randomized Study of the Immunogenicity, Safety and Tolerability of an RSV Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine.
    J Infect Dis. 2021 Dec 21. pii: 6472733. doi: 10.1093.
    PubMed     Abstract available


  363. IYER AS, Harris JB
    Correlates of Protection for Cholera.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  364. SAHA GK, Ganguly NK
    Spread and Endemicity of Cholera in India: Factors Beyond the Numbers.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  365. CHAO DL
    Mathematical Modeling of Endemic Cholera Transmission.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  366. SACK DA, Debes AK, Ateudjieu J, Bwire G, et al
    Contrasting Epidemiology of Cholera in Bangladesh and Africa.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  367. FLECKENSTEIN JM, Sheikh A
    Emerging Themes in the Molecular Pathogenesis of Enterotoxigenic Escherichia coli.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  368. BRUNHAM RC
    Problems with Understanding Chlamydia trachomatis Immunology.
    J Infect Dis. 2021 Dec 17. pii: 6469012. doi: 10.1093.
    PubMed     Abstract available


  369. HASTIE A, Catteau G, Enemuo A, Mrkvan T, et al
    Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
    J Infect Dis. 2021;224:2025-2034.
    PubMed     Abstract available


  370. HUI BB, Padeniya TN, Rebuli N, Gray RT, et al
    A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men.
    J Infect Dis. 2021 Dec 11. pii: 6459455. doi: 10.1093.
    PubMed     Abstract available


  371. CHRISTENSEN H, Vickerman P
    Gonococcal vaccines for controlling Neisseria gonorrhoeae in men who have sex with men: a promising game-changer.
    J Infect Dis. 2021 Dec 11. pii: 6459454. doi: 10.1093.
    PubMed    


  372. BROCKMAN MA, Mwimanzi F, Lapointe HR, Sang Y, et al
    Reduced magnitude and durability of humoral immune responses to COVID-19 mRNA vaccines among older adults.
    J Infect Dis. 2021 Dec 9. pii: 6458430. doi: 10.1093.
    PubMed     Abstract available


  373. NARANBHAI V, Garcia-Beltran WF, Chang CC, Mairena CB, et al
    Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines.
    J Infect Dis. 2021 Dec 9. pii: 6458467. doi: 10.1093.
    PubMed     Abstract available


    November 2021
  374. GILBOA M, Mandelboim M, Indenbaum V, Lustig Y, et al
    Early Immunogenicity and safety of the third dose of BNT162b2 mRNA Covid-19 vaccine among adults older than 60 years; real world experience.
    J Infect Dis. 2021 Nov 29. pii: 6446235. doi: 10.1093.
    PubMed     Abstract available


  375. JOHNSON MJ, Liu C, Ghosh D, Lang N, et al
    Cell-Mediated Immune Responses After Administration Of The Live Or The Recombinant Zoster Vaccine: Five-Year Persistence.
    J Infect Dis. 2021 Nov 27. pii: 6444689. doi: 10.1093.
    PubMed     Abstract available


  376. KIM JY, Lim SY, Park S, Kwon JS, et al
    Immune responses to the ChAdOx1 nCoV-19 and BNT162b2 vaccines and to natural COVID-19 infections over a three-month period.
    J Infect Dis. 2021 Nov 25. pii: 6440288. doi: 10.1093.
    PubMed     Abstract available


  377. RYCKMAN T, Karthikeyan AS, Kumar D, Cao Y, et al
    Comparison of Strategies for Typhoid Conjugate Vaccine Introduction in India: A Cost-Effectiveness Modeling Study.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  378. KUMAR S, Ghosh RS, Iyer H, Ray A, et al
    Typhoid in India: An Age-old Problem With an Existing Solution.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  379. CAO Y, Karthikeyan AS, Ramanujam K, Raju R, et al
    Geographic Pattern of Typhoid Fever in India: A Model-Based Estimate of Cohort and Surveillance Data.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  380. SINHA B, Rongsen-Chandola T, Goyal N, Arya A, et al
    Incidence of Enteric Fever in a Pediatric Cohort in North India: Comparison with Estimates from 20 Years Earlier.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  381. MOHAN VR, Srinivasan M, Sinha B, Shrivastava A, et al
    Geographically Weighted Regression Modeling of Spatial Clustering and Determinants of Focal Typhoid Fever Incidence.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  382. AMBROSINO D, Han HH, Hu B, Liang J, et al
    Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
    J Infect Dis. 2021 Nov 19. pii: 6431853. doi: 10.1093.
    PubMed     Abstract available


  383. FULDA ES, Fitch KV, Overton ET, Zanni MV, et al
    COVID-19 Vaccination Rates in a Global HIV Cohort.
    J Infect Dis. 2021 Nov 18. pii: 6431673. doi: 10.1093.
    PubMed     Abstract available


  384. COLLIER AY, Yu J, Mcmahan K, Liu J, et al
    COVID-19 mRNA Vaccine Immunogenicity in Immunosuppressed Individuals.
    J Infect Dis. 2021 Nov 18. pii: 6430790. doi: 10.1093.
    PubMed     Abstract available


  385. ALAM MM, Ikram A, Mahmood N, Sharif S, et al
    Antigenic structure of wild poliovirus type 1 strains endemic in Pakistan is highly conserved and completely neutralized by Sabin's Oral Polio Vaccine.
    J Infect Dis. 2021 Nov 17. pii: 6430438. doi: 10.1093.
    PubMed     Abstract available


  386. DUARTE G, Muresan P, Ward S, Laimon L, et al
    Immunogenicity of conjugated and polysaccharide pneumococcal vaccines administered during pregnancy or postpartum to women with HIV.
    J Infect Dis. 2021 Nov 16. pii: 6429421. doi: 10.1093.
    PubMed     Abstract available


  387. BIERLE DM, Ganesh R, Tulledge-Scheitel S, Hanson SN, et al
    Monoclonal Antibody Treatment of Breakthrough COVID-19 in Fully Vaccinated Individuals with High-Risk Comorbidities.
    J Infect Dis. 2021 Nov 16. pii: 6429422. doi: 10.1093.
    PubMed     Abstract available


  388. JOHNSON S, Martinez CI, Tedjakusuma SN, Peinovich N, et al
    Oral vaccination protects against SARS-CoV-2 in a Syrian hamster challenge model.
    J Infect Dis. 2021 Nov 10. pii: 6425228. doi: 10.1093.
    PubMed     Abstract available


  389. STOCKDALE AJ, Meiring JE, Shawa IT, Thindwa D, et al
    Hepatitis B vaccination impact and the unmet need for antiviral treatment in Blantyre, Malawi.
    J Infect Dis. 2021 Nov 9. pii: 6424415. doi: 10.1093.
    PubMed     Abstract available


  390. FERREIRA VH, Marinelli T, Ierullo M, Ku T, et al
    SARS-CoV-2 infection induces greater T-cell responses compared to vaccination in solid organ transplant recipients.
    J Infect Dis. 2021 Nov 5. pii: 6406613. doi: 10.1093.
    PubMed     Abstract available


  391. SACIUK Y, Kertes J, Shamir Stein N, Ekka Zohar A, et al
    Effectiveness of a third dose of BNT162b2 mRNA vaccine.
    J Infect Dis. 2021 Nov 2. pii: 6415586. doi: 10.1093.
    PubMed     Abstract available


    October 2021
  392. MEIJIDE MIGUEZ H, Ochando Gomez M, Montes Garcia I, Garcia Merino IM, et al
    Cellular and humoral response, six months after two doses of BNT162b2 mRNA Covid 19 vaccination, in residents and staff of nursing homes for the elderly.
    J Infect Dis. 2021 Oct 28. pii: 6413766. doi: 10.1093.
    PubMed    


  393. CHAKRABORTY D, Kanungo S, Nandy RK, Deb AK, et al
    Challenges for Programmatic Implementation of Oral Cholera Vaccine in India.
    J Infect Dis. 2021 Oct 20. pii: 6404482. doi: 10.1093.
    PubMed     Abstract available


  394. CALLEGARO A, Burny W, Herve C, Kim JH, et al
    Association between immunogenicity and reactogenicity: a post hoc analysis of two Phase 3 studies with the adjuvanted recombinant zoster vaccine.
    J Infect Dis. 2021 Oct 18. pii: 6400271. doi: 10.1093.
    PubMed     Abstract available


  395. WITHANAGE K, De Coster I, Cools N, Viviani S, et al
    Phase 1 randomized, placebo-controlled, dose-escalating study to evaluate OVX836, a nucleoprotein-based influenza vaccine: intramuscular results.
    J Infect Dis. 2021 Oct 15. pii: 6398205. doi: 10.1093.
    PubMed     Abstract available


  396. PRENTICE S, Dockrell HM
    BCG Specific and Nonspecific Effects: Different Questions, Similar Challenges.
    J Infect Dis. 2021;224:1105-1108.
    PubMed    


  397. WILLIAMS FB, Kader A, Colgate ER, Dickson DM, et al
    Maternal Secretor Status Affects Oral Rotavirus Vaccine Response in Breastfed Infants in Bangladesh.
    J Infect Dis. 2021;224:1147-1151.
    PubMed     Abstract available


  398. DAGNEW AF, Klein NP, Herve C, Kalema G, et al
    The Adjuvanted Recombinant Zoster Vaccine in Adults Aged >/=65 Years Previously Vaccinated With a Live-Attenuated Herpes Zoster Vaccine.
    J Infect Dis. 2021;224:1139-1146.
    PubMed     Abstract available


  399. PETERSON JT, Zareba AM, Fitz-Patrick D, Essink BJ, et al
    Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Co-Administered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine.
    J Infect Dis. 2021 Oct 12. pii: 6391485. doi: 10.1093.
    PubMed     Abstract available


  400. DILLER JR, Carter MH, Kanai Y, Sanchez SV, et al
    Monoreassortant rotaviruses of multiple G types are differentially neutralized by sera from infants vaccinated with ROTARIX(R) and RotaTeq(R).
    J Infect Dis. 2021 Oct 10. pii: 6386353. doi: 10.1093.
    PubMed     Abstract available


  401. DODD RY, Notari EP, Brodsky JP, Foster GA, et al
    Patterns of antibody response to SARS-CoV-2 among 1.6 million blood donors: Impact of vaccination, United States December 2020 - June 2021.
    J Infect Dis. 2021 Oct 9. pii: 6385747. doi: 10.1093.
    PubMed     Abstract available


  402. LU Y, Jiao Y, Graham DJ, Wu Y, et al
    Risk factors for COVID-19 deaths among elderly nursing home Medicare beneficiaries in the pre-vaccine period.
    J Infect Dis. 2021 Oct 7. pii: 6383455. doi: 10.1093.
    PubMed     Abstract available


  403. GAST C, Bandyopadhyay AS, Saez-Llorens X, De Leon T, et al
    Fecal shedding of two novel live attenuated oral poliovirus type 2 vaccines candidates by healthy bOPV/IPV-vaccinated infants: two randomized clinical trials.
    J Infect Dis. 2021 Oct 5. pii: 6381642. doi: 10.1093.
    PubMed     Abstract available


  404. GERSHON AA, Gershon MD
    Widespread use of varicella vaccine does not reduce immunity to zoster of others.
    J Infect Dis. 2021 Oct 5. pii: 6381628. doi: 10.1093.
    PubMed    


  405. CARRYN S, Cheuvart B, Povey M, Dagnew AF, et al
    No consistent evidence of decreased exposure to varicella-zoster virus among older adults in countries with universal varicella vaccination.
    J Infect Dis. 2021 Oct 5. pii: 6381619. doi: 10.1093.
    PubMed     Abstract available


    September 2021
  406. GLASS RI, Tate JE, Jiang B, Parashar U, et al
    The Rotavirus Vaccine Story: From Discovery to the Eventual Control of Rotavirus Disease.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  407. MARKOWITZ LE, Schiller JT
    Human Papillomavirus Vaccines.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  408. GERSHON AA, Gershon MD, Shapiro ED
    Live Attenuated Varicella Vaccine: Prevention of Varicella and of Zoster.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  409. BECKER T, Elbahesh H, Reperant LA, Rimmelzwaan GF, et al
    Influenza Vaccines: Successes and Continuing Challenges.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  410. PATTYN J, Hendrickx G, Vorsters A, Van Damme P, et al
    Hepatitis B Vaccines.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  411. RODGERS GL, Whitney CG, Klugman KP
    Triumph of Pneumococcal Conjugate Vaccines: Overcoming a Common Foe.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  412. HARBECKE R, Cohen JI, Oxman MN
    Herpes Zoster Vaccines.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  413. GILSDORF JR
    Hib Vaccines: Their Impact on Haemophilus influenzae Type b Disease.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  414. BREMAN JG
    Smallpox.
    J Infect Dis. 2021;224.
    PubMed    


  415. MODLIN JF, Bandyopadhyay AS, Sutter R
    Immunization Against Poliomyelitis and the Challenges to Worldwide Poliomyelitis Eradication.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  416. PLOTKIN SA
    Rubella Eradication: Not Yet Accomplished, but Entirely Feasible.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  417. DECKER MD, Edwards KM
    Pertussis (Whooping Cough).
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  418. GASTANADUY PA, Goodson JL, Panagiotakopoulos L, Rota PA, et al
    Measles in the 21st Century: Progress Toward Achieving and Sustaining Elimination.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


  419. KARBIENER M, Farcet MR, Schwaiger J, Powers N, et al
    Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins.
    J Infect Dis. 2021 Sep 20. pii: 6372887. doi: 10.1093.
    PubMed     Abstract available


  420. FERREIRA IATM, Kemp SA, Datir R, Saito A, et al
    SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
    J Infect Dis. 2021;224:989-994.
    PubMed     Abstract available


  421. PROBERT WS, Glenn-Finer R, Espinosa A, Yen C, et al
    Molecular Epidemiology of Measles in California, United States-2019.
    J Infect Dis. 2021;224:1015-1023.
    PubMed     Abstract available


  422. GORSE GJ, Rattigan SM, Kirpich A, Simberkoff MS, et al
    Influence of Pre-Season Antibodies against Influenza Virus on Risk of Influenza Infection among Health Care Personnel.
    J Infect Dis. 2021 Sep 17. pii: 6371937. doi: 10.1093.
    PubMed     Abstract available


  423. VAN PRAET JT, Vandecasteele S, De Roo A, Vynck M, et al
    Dynamics of the cellular and humoral immune response after BNT162b2 mRNA Covid-19 vaccination in Covid-19 naive nursing home residents.
    J Infect Dis. 2021 Sep 13. pii: 6369254. doi: 10.1093.
    PubMed     Abstract available


  424. KIM SS, Chung JR, Belongia EA, McLean HQ, et al
    mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >/=16 Years in the United States, February - May 2021.
    J Infect Dis. 2021 Sep 8. pii: 6366365. doi: 10.1093.
    PubMed     Abstract available


  425. RICHMOND PC, Hatchuel L, Pacciarini F, Hu B, et al
    Persistence of the immune responses and cross-neutralizing activity with Variants of Concern following two doses of adjuvanted SCB-2019 COVID-19 vaccine.
    J Infect Dis. 2021 Sep 4. pii: 6364149. doi: 10.1093.
    PubMed     Abstract available


  426. DU PLESSIS M, de Gouveia L, Freitas C, Abera NA, et al
    The Role of Molecular Testing in Pediatric Meningitis Surveillance in Southern and East African Countries, 2008-2017.
    J Infect Dis. 2021;224.
    PubMed     Abstract available


    August 2021
  427. GIURGEA LT, Cervantes-Medina A, Walters KA, Scherler K, et al
    Sex Differences in Influenza: The Challenge Study Experience.
    J Infect Dis. 2021 Aug 23. pii: 6356350. doi: 10.1093.
    PubMed     Abstract available


  428. MAN I, Vanska S, Lehtinen M, Bogaards JA, et al
    Human Papillomavirus Genotype Replacement: Still Too Early to Tell?
    J Infect Dis. 2021;224:481-491.
    PubMed     Abstract available


    June 2021
  429. WHITEHOUSE ER, Bonwitt J, Hughes CM, Lushima RS, et al
    Clinical and Epidemiological Findings from Enhanced Monkeypox Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011-2015.
    J Infect Dis. 2021;223:1870-1878.
    PubMed     Abstract available


    April 2021
  430. WILHELM M, Kaur A, Wernli M, Hirsch HH, et al
    BK Polyomavirus-Specific CD8 T-Cell Expansion In Vitro Using 27mer Peptide Antigens for Developing Adoptive T-Cell Transfer and Vaccination.
    J Infect Dis. 2021;223:1410-1422.
    PubMed     Abstract available


  431. EL SAHLY HM, Atmar RL, Sendra E, Wegel A, et al
    Topical Imiquimod Does not Provide an Adjuvant Effect when Administered with Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults.
    J Infect Dis. 2021 Apr 14. pii: 6225864. doi: 10.1093.
    PubMed     Abstract available


  432. BLUMENFELD O, Hampe CS, Shulman LM, Chen R, et al
    An Attenuation in the Incidence of Early Childhood Diabetes Correlates With Introduction of Rotavirus Vaccination in Israel.
    J Infect Dis. 2021;223:1305-1307.
    PubMed    


  433. SALEEM AF, Mach O, Yousafzai MT, Kazi Z, et al
    One-Year Decline of Poliovirus Antibodies Following Fractional-Dose Inactivated Poliovirus Vaccine.
    J Infect Dis. 2021;223:1214-1221.
    PubMed     Abstract available


  434. BEALL B, Walker H, Tran T, Li Z, et al
    Upsurge of Conjugate Vaccine Serotype 4 Invasive Pneumococcal Disease Clusters Among Adults Experiencing Homelessness in California, Colorado, and New Mexico.
    J Infect Dis. 2021;223:1241-1249.
    PubMed     Abstract available


  435. RAMAN R, Brennan J, Ndi D, Sloan C, et al
    Marked Reduction of Socioeconomic and Racial Disparities in Invasive Pneumococcal Disease Associated With Conjugate Pneumococcal Vaccines.
    J Infect Dis. 2021;223:1250-1259.
    PubMed     Abstract available


  436. WAGSTAFFE HR, Clutterbuck EA, Bockstal V, Stoop JN, et al
    Antibody-Dependent Natural Killer Cell Activation After Ebola Vaccination.
    J Infect Dis. 2021;223:1171-1182.
    PubMed     Abstract available


    March 2021
  437. JORDAN E, Lawrence SJ, Meyer TPH, Schmidt D, et al
    Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine.
    J Infect Dis. 2021;223:1062-1072.
    PubMed     Abstract available


    January 2021
  438. DE PIJPER CA, Langedijk AC, Terryn S, Van Gucht S, et al
    Long-term memory response after a single intramuscular rabies booster vaccination, 10-24 years after primary immunization.
    J Infect Dis. 2021 Jan 27. pii: 6121364. doi: 10.1093.
    PubMed     Abstract available


    September 2020
  439. TOTA JE, Struyf F, Hildesheim A, Gonzalez P, et al
    Efficacy of AS04-adjuvanted HPV-16/18 vaccine against clearance of incident HPV infections: Pooled analysis of data from the CVT and PATRICIA randomized trials.
    J Infect Dis. 2020 Sep 5. pii: 5901687. doi: 10.1093.
    PubMed     Abstract available


    August 2020
  440. SADOFF J, De Paepe E, Haazen W, Omoruyi E, et al
    Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults.
    J Infect Dis. 2020 Aug 26. pii: 5897745. doi: 10.1093.
    PubMed     Abstract available


  441. PANG Y, Wang Q, Lv M, Yu M, et al
    Influenza vaccination protects against hospitalization outcomes among older patients with cardiovascular or respiratory diseases.
    J Infect Dis. 2020 Aug 11. pii: 5890841. doi: 10.1093.
    PubMed     Abstract available


    July 2020
  442. CAMPBELL N, Verrall AJ, Donkor S, Sutherland JS, et al
    BCG protection against Mycobacterium tuberculosis infection by level of exposure in The Gambia.
    J Infect Dis. 2020 Jul 8. pii: 5868549. doi: 10.1093.
    PubMed     Abstract available


  443. HU SY, Tsang SH, Chen F, Pan QJ, et al
    Association between Common Vaginal Infections and Cervical Non-HPV16/18 Infection in HPV-Vaccinated Women.
    J Infect Dis. 2020 Jul 2. pii: 5866538. doi: 10.1093.
    PubMed     Abstract available


    April 2020
  444. SCHWENDINGER M, Thiry G, De Vos B, Leroux-Roels G, et al
    A Randomized Dose-Escalating Phase I Trial of a Replication-Deficient Lymphocytic Choriomeningitis Virus Vector-Based Vaccine Against Human Cytomegalovirus.
    J Infect Dis. 2020 Apr 21. pii: 5821369. doi: 10.1093.
    PubMed     Abstract available


    March 2020
  445. KURTOVIC L, Atre T, Feng G, Wines BD, et al
    Multi-functional antibodies are induced by the RTS,S malaria vaccine and associated with protection in a phase I/IIa trial.
    J Infect Dis. 2020 Mar 31. pii: 5814271. doi: 10.1093.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Vaccines is free of charge.